CA2624486A1 - Novel sea lice vaccine - Google Patents
Novel sea lice vaccine Download PDFInfo
- Publication number
- CA2624486A1 CA2624486A1 CA002624486A CA2624486A CA2624486A1 CA 2624486 A1 CA2624486 A1 CA 2624486A1 CA 002624486 A CA002624486 A CA 002624486A CA 2624486 A CA2624486 A CA 2624486A CA 2624486 A1 CA2624486 A1 CA 2624486A1
- Authority
- CA
- Canada
- Prior art keywords
- protein
- acid sequence
- nucleic acid
- immunogenic fragment
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 114
- 241001674048 Phthiraptera Species 0.000 title claims abstract description 56
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 440
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 416
- 239000012634 fragment Substances 0.000 claims abstract description 127
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 106
- 208000015181 infectious disease Diseases 0.000 claims abstract description 37
- 108020004414 DNA Proteins 0.000 claims abstract description 34
- 238000000034 method Methods 0.000 claims abstract description 23
- 108020004511 Recombinant DNA Proteins 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- 230000002163 immunogen Effects 0.000 claims description 101
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 69
- 239000000427 antigen Substances 0.000 claims description 42
- 102000036639 antigens Human genes 0.000 claims description 42
- 108091007433 antigens Proteins 0.000 claims description 42
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 40
- 235000019688 fish Nutrition 0.000 claims description 38
- 241000251468 Actinopterygii Species 0.000 claims description 36
- 239000003937 drug carrier Substances 0.000 claims description 18
- 241000700605 Viruses Species 0.000 claims description 16
- 102000053602 DNA Human genes 0.000 claims description 11
- 241000711804 Infectious hematopoietic necrosis virus Species 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 241000711825 Viral hemorrhagic septicemia virus Species 0.000 claims description 5
- 230000002068 genetic effect Effects 0.000 claims description 5
- 241000710921 Infectious pancreatic necrosis virus Species 0.000 claims description 4
- 241001492212 Striped Jack nervous necrosis virus Species 0.000 claims description 4
- 244000005700 microbiome Species 0.000 claims description 4
- 241000546112 Infectious salmon anemia virus Species 0.000 claims description 3
- 241000544286 Vibrio anguillarum Species 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- 241000607525 Aeromonas salmonicida Species 0.000 claims description 2
- 241000607471 Edwardsiella tarda Species 0.000 claims description 2
- 241000604777 Flavobacterium columnare Species 0.000 claims description 2
- 241001517024 Photobacterium damselae subsp. piscicida Species 0.000 claims description 2
- 241000186812 Renibacterium salmoninarum Species 0.000 claims description 2
- 241001148129 Yersinia ruckeri Species 0.000 claims description 2
- 208000024691 pancreas disease Diseases 0.000 claims description 2
- 239000000969 carrier Substances 0.000 abstract description 10
- 241000277331 Salmonidae Species 0.000 abstract description 8
- 235000018102 proteins Nutrition 0.000 description 328
- 210000004027 cell Anatomy 0.000 description 33
- 241000283973 Oryctolagus cuniculus Species 0.000 description 31
- 102000002322 Egg Proteins Human genes 0.000 description 28
- 108010000912 Egg Proteins Proteins 0.000 description 28
- 241001247234 Lepeophtheirus salmonis Species 0.000 description 27
- 235000013601 eggs Nutrition 0.000 description 25
- 108090000765 processed proteins & peptides Proteins 0.000 description 24
- 238000001262 western blot Methods 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 23
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 21
- 238000002255 vaccination Methods 0.000 description 17
- 239000002299 complementary DNA Substances 0.000 description 16
- 238000002965 ELISA Methods 0.000 description 14
- 241000277263 Salmo Species 0.000 description 14
- 241000972773 Aulopiformes Species 0.000 description 12
- 235000019515 salmon Nutrition 0.000 description 12
- 241001235719 Caligus curtus Species 0.000 description 11
- 241001611004 Caligus rogercresseyi Species 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 229920000136 polysorbate Polymers 0.000 description 8
- 108020001580 protein domains Proteins 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 241001611011 Caligus Species 0.000 description 7
- 241000239250 Copepoda Species 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 241000277289 Salmo salar Species 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 5
- 244000078703 ectoparasite Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 210000000287 oocyte Anatomy 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 101710204837 Envelope small membrane protein Proteins 0.000 description 4
- 101710145006 Lysis protein Proteins 0.000 description 4
- 238000000636 Northern blotting Methods 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000008488 polyadenylation Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241001405819 Caligus elongatus Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 3
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 241000277288 Salmo trutta Species 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 238000009360 aquaculture Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000009313 farming Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000007654 immersion Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000000575 pesticide Substances 0.000 description 3
- 229960000856 protein c Drugs 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- 241000710929 Alphavirus Species 0.000 description 2
- 241000238582 Artemia Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 101710117545 C protein Proteins 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- 101000802895 Dendroaspis angusticeps Fasciculin-1 Proteins 0.000 description 2
- 241000724791 Filamentous phage Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 241000276438 Gadus morhua Species 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 2
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 2
- 208000001388 Opportunistic Infections Diseases 0.000 description 2
- 241000700141 Rotifera Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 241000607598 Vibrio Species 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 244000144974 aquaculture Species 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000012405 in silico analysis Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 241000238569 Artemia sp. Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000276457 Gadidae Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001112535 Novirhabdovirus Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- 101710188053 Protein D Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101710132893 Resolvase Proteins 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 241000316146 Salmo trutta trutta Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000318 alkali metal phosphate Inorganic materials 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002353 niosome Substances 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Abstract
The present invention relates to a 200 kD protein, a 180 kD protein, a 100/85 kD protein and a 79 kD protein. The invention further relates too nucleic acid sequences encoding a 200 kD protein, a 180 kD protein, a 100/85 kD protein and a79 kD protein, to vaccines comprising these proteins or a nucleic acid sequences encoding the proteins, to DNA fragments, recombinant DNA molecules, live recombinant carriers and to host cells comprising such nucleic acid sequences, to vaccines comprising such DNA fragments, recombinant DNA
molecules, live recombinant carriers and to host cells comprising such nucleic acid sequences, to methods for the preparation of such vaccines and to the use of such protein or nucleic acid sequences encoding such protein in vaccines and for the manufacture of a vaccine for combating sea lice infection in salmonids.
molecules, live recombinant carriers and to host cells comprising such nucleic acid sequences, to methods for the preparation of such vaccines and to the use of such protein or nucleic acid sequences encoding such protein in vaccines and for the manufacture of a vaccine for combating sea lice infection in salmonids.
Description
DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE I)E CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.
CECI EST LE TOME DE _2 NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.
NOTE: For additional volumes please contact the Canadian Patent Office.
Novel sea lice vaccine.
The present invention relates to a 200 kD protein, a 180 kD protein, a 100/85 kD
protein and a 79 kD protein. The invention further relates to nucleic acid sequences encoding a 200 kD protein, a 180 kD protein, a 100/85 kD protein and a79 kD
protein, to vaccines comprising these proteins or a nucleic acid sequences encoding the proteins, to DNA fragments, recombinant DNA molecules, live recombinant carriers and to host cells comprising such nucleic acid sequences, to vaccines comprising such DNA fragments, recombinant DNA molecules, live recombinant carriers and to host cells comprising such nucleic acid sequences, to methods for the preparation of such vaccines and to the use of such protein or nucleic acid sequences encoding such protein in vaccines and for the manufacture of a vaccine for combating sea lice infection in salmonids.
Sea lice form a group of ectoparasites that have marine fish as host. They are in some cases host specific. Merely as an example; the salmon louse (Lepeophtheirus salmonis (Kroyer)) is host specific in that it infects salmonids only. However, most sea lice are to a variable degree not host specific, infecting different marine fish including salmonids and cods. Caligus rogercresseyi is mostly found on salmonids while Caligus curtus is mostly found on non-salmonids. One of the least host specific sea lice, Caligus elongatus, has been isolated from more than 80 different species of fish.
The salmon louse Lepeophtheirus salmonis is a marine ectoparasitic copepod feeding on skin, mucus and blood of salmonid hosts. The louse has ten developmental stages of which two stages are free living in the water, one is infectious and seven stages are parasitic (reviewed in Pike, A.W. and Wadsworth, S.L., Adv. Parasitol. 44: 233-(1999)).
Although under natural conditions both species are usually found in low numbers, L.
salmonis can cause significant harm to both the wild Atlantic salmon (Salmo salar) and the sea trout (Salmo trutta). Salmo salar is grown more and more frequently in aquaculture, leading to a high local density of hosts for sea lice. As a consequence, infection with sea lice of salmon in aqua-farming is clearly increasing.
LA PRESENTE PARTIE I)E CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.
CECI EST LE TOME DE _2 NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.
NOTE: For additional volumes please contact the Canadian Patent Office.
Novel sea lice vaccine.
The present invention relates to a 200 kD protein, a 180 kD protein, a 100/85 kD
protein and a 79 kD protein. The invention further relates to nucleic acid sequences encoding a 200 kD protein, a 180 kD protein, a 100/85 kD protein and a79 kD
protein, to vaccines comprising these proteins or a nucleic acid sequences encoding the proteins, to DNA fragments, recombinant DNA molecules, live recombinant carriers and to host cells comprising such nucleic acid sequences, to vaccines comprising such DNA fragments, recombinant DNA molecules, live recombinant carriers and to host cells comprising such nucleic acid sequences, to methods for the preparation of such vaccines and to the use of such protein or nucleic acid sequences encoding such protein in vaccines and for the manufacture of a vaccine for combating sea lice infection in salmonids.
Sea lice form a group of ectoparasites that have marine fish as host. They are in some cases host specific. Merely as an example; the salmon louse (Lepeophtheirus salmonis (Kroyer)) is host specific in that it infects salmonids only. However, most sea lice are to a variable degree not host specific, infecting different marine fish including salmonids and cods. Caligus rogercresseyi is mostly found on salmonids while Caligus curtus is mostly found on non-salmonids. One of the least host specific sea lice, Caligus elongatus, has been isolated from more than 80 different species of fish.
The salmon louse Lepeophtheirus salmonis is a marine ectoparasitic copepod feeding on skin, mucus and blood of salmonid hosts. The louse has ten developmental stages of which two stages are free living in the water, one is infectious and seven stages are parasitic (reviewed in Pike, A.W. and Wadsworth, S.L., Adv. Parasitol. 44: 233-(1999)).
Although under natural conditions both species are usually found in low numbers, L.
salmonis can cause significant harm to both the wild Atlantic salmon (Salmo salar) and the sea trout (Salmo trutta). Salmo salar is grown more and more frequently in aquaculture, leading to a high local density of hosts for sea lice. As a consequence, infection with sea lice of salmon in aqua-farming is clearly increasing.
For Caligus infections in cod, the same will happen in the foreseeable future, due to the increasing importance of cod farming.
Newly started cod production amounted to 605 tons only. However, given the fact that only in the UK, cod consumption is 170.000 tons yearly, and given the sharp reduction in European catch limits, it is clear that cod farming commercially becomes more and more attractive.
Louse infection as such is seldom the direct cause of illness and death, since sea lice feed primarily on mucus and skin. This however causes damage to both mucus and skin, making the host more vulnerable to opportunistic infections. These opportunistic infections thus are the direct cause of increasingly significant economic losses.
Classical treatment with organophosphate pesticides such as Nevugon and Aquagard is no longer an option. This is due to the fact that lice are developing an increasing resistance to such pesticides, and to the fact that such pesticides are no longer acceptable from an environmental point of view.
Therefore, vaccines against sea lice are highly desirable. Up till now, however, no such vaccines are on the market.
The search for suitable vaccine candidates has been going on for many years already.
This approach has however so far not led to vaccines for combating sea lice infection.
It is an objective of the present invention to provide a novel vaccine that is capable of inducing in susceptible fish such as i.a. Salmo salar, Salmo trutta and cod, a degree of protection against sea lice infection and to the effects of the infection.
Surprisingly it was found now, that several proteins could be isolated from the eggs of adult egg producing sea lice, more specifically Lepeophtheirus salmonis, Caligus rogercresseyi, Caligus elongatus and Caligus curtus, that are capable of inducing antibodies in Salmo salar, Salmo trutta and cod to the extent that fish vaccinated with these proteins are to an efficient degree protected against sea lice infection and the effects thereof.
Even more surprisingly, a strong cross-reactivity between antibodies against the 200 kD protein, the 180 kD protein, the 100/85 kD protein and the 79 kD protein respectively of one species and the homologous 200 kD protein, the 180 kD
protein, the 100/85 kD protein and the 79 kD protein in other species appered to exist.
Antibodies raised against this 200 kD protein, the 180 kD protein, the 100/85 kD
protein and the 79 kD protein from e.g. Lepeophtheirus salmonis additionally appeared to react strongly in a Western blot with homologous proteins from Caligus curtus and Caligus rogercresseyi.
As will be further clarified below, a first embodiment of the present invention relates to this 200 kD protein.
A second embodiment of the present invention relates to this 180 kD protein.
A third embodiment of the present invention relates to this 100/85 kD protein.
A fourth embodiment of the present invention relates to this 79 kD protein.
It is well-known in the art, that many different nucleic acid sequences can encode one and the same protein. This phenomenon is commonly known as wobble in the second and especially the third base of each triplet encoding an amino acid. This phenomenon can result in a heterology of about 30% for two nucleic acid sequences still encoding the same protein. Therefore, two nucleic acid sequences having an overall sequence identity as low as 70 % can still encode one and the same protein.
It will also be understood that, for the particular proteins embraced herein, natural variations can exist between individual sea lice strains. These variations may be demonstrated by (an) amino acid difference(s) in the overall sequence or by deletions, substitutions, insertions, inversions or additions of (an) amino acid(s) in said sequence. Amino acid substitutions which do not essentially alter biological and immunological activities, have been described, e.g. by Neurath et al. in "The Proteins"
Academic Press New York (1979). Amino acid replacements between related amino acids or replacements which have occurred frequently in evolution are, inter alia, Ser/Ala, Ser/Gly, Asp/Gly, Asp/Asn, Ile/Val (see Dayhof, M.D., Atlas of protein sequence and structure, Nat. Biomed. Res. Found., Washington D.C., 1978, vol.
5, suppl. 3). Other amino acid substitutions include Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Thr/Phe, Ala/Pro, Lys/Arg, Leu/Ile, Leu/Val and Ala/Glu.
Based on this information, Lipman and Pearson developed a method for rapid and sensitive protein comparison (Science,227, 1435-1441, 1985) and determining the functional similarity between identical proteins. Such amino acid substitutions of the exemplary embodiments of this invention, as well as variations having deletions and/or insertions are within the scope of the invention as long as the resulting proteins retain their immune reactivity. This explains why sea lice proteins according to the invention, when isolated from different field isolates, may have identity levels of about 70%, while still representing the same protein with the same immunological characteristics.
Those variations in the amino acid sequence of a certain protein according to the invention that still provide a protein capable of inducing an immune response against infection with sea lice or at least against the clinical manifestations of the infection are considered as "not essentially influencing the immunological characteristics".
Therefore, the protein according to the invention comprises those proteins and immunogenic fragments thereof that have an amino acid sequence that is at least 70%
identical to the amino acid sequence of the 200 kD protein as depicted in SEQ
ID NO:
2, the 180 kD protein as depicted in SEQ ID NO: 4, the 100/85kD protein as depicted in SEQ ID NO: 6 or the 79 kD protein as depicted in SEQ ID NO: 8.
Thus, one embodiment of the present invention relates to a 200 kD protein or an immunogenic fragment thereof, said protein or immunogenic fragment thereof having an amino acid sequence that is at least 70% identical to the amino acid sequence as depicted in SEQ ID NO: 2.
An immunogenic fragment is a fragment that has a length of at least 50 amino acids.
The concept of immunogenic fragments will be defined below.
Preferably, the amino acid sequence of a 200 kD protein or an immunogenic fragment of that protein has at least 75%, or more preferably 80% identity with the amino acid sequence of SEQ ID NO: 2. Even more preferred is a identity level of 85%, 90%, 92%, 94%, 95% 96%, 97%, 98%, 99% or even 100% in that order of preference.
Therefore, a preferred form of this embodiment relates to a 200 kD protein or an immunogenic fragment of said protein according to the invention wherein said protein or immunogenic fragment thereof has a sequence identity of at least 70%, preferably 75%, more preferably 80% or even 85%, 90%, 92%, preferably 94%, more preferably 95%, even more preferred 96%, 97%, 98%, 99% or even 100% in that order of preference identity with the amino acid sequence of SEQ ID NO: 2.
A most preferred form of this embodiment relates to a 200 kD protein or an 5 immunogenic fragment of said protein, according to the invention as encoded by a nucleic acid sequence described in SEQ ID NO: 1.
The level of protein identity can e.g. be determined with the computer program "BLAST 2 SEQUENCES" by selecting sub-program: "BLASTP", that can be found at www.ncbi.nlm.nih.l!ov/blast/bl2seg/b12.htm1.
A reference for this program is Tatiana A. Tatusova, Thomas L. Madden FEMS
Microbiol. Letters 174: 247-250 (1999). Matrix used: "blosum62". Parameters used are the default parameters:
Open gap: 11. Extension gap: 1. Gap x_dropoff: 50.
Amino acid sequences that comprise tandem arrays of the sequences according to the invention are also within the scope of the invention.
A second embodiment of the present invention relates to a 180 kD protein or an immunogenic fragment thereof, said protein or immunogenic fragment thereof having an amino acid sequence that is at least 70% identical to the amino acid sequence as depicted in SEQ ID NO: 4.
Preferably, the amino acid sequence of the 180 kD protein or an immunogenic fragment of that protein has at least 75%, or more preferably 80% identity with the amino acid sequence of SEQ ID NO: 4. Even more preferred is a identity level of 85%, 90%, 92%, 94%, 95% 96%, 97%, 98%, 99% or even 100% in that order of preference.
Therefore, a preferred form of this embodiment relates to a 180 kD protein or an immunogenic fragment of said protein according to the invention wherein said protein or immunogenic fragment thereof has a sequence identity of at least 70%, preferably 75%, more preferably 80% or even 85%, 90%, 92%, preferably 94%, more preferably 95%, even more preferred 96%, 97%, 98%, 99% or even 100% in that order of preference identity with the amino acid sequence of SEQ ID NO: 4.
A most preferred form of this embodiment relates to a 180 kD protein or an immunogenic fragment of said protein, according to the invention as encoded by a nucleic acid sequence described in SEQ ID NO: 3.
A third embodiment of the present invention relates to a 100/85 kD protein or an immunogenic fragment thereof, said protein or immunogenic fragment thereof having an amino acid sequence that is at least 70% identical to the amino acid sequence as depicted in SEQ ID NO: 6.
Preferably, the amino acid sequence of the 100/85 kD protein or an immunogenic fragment of that protein has at least 75%, or more preferably 80% identity with the amino acid sequence of SEQ ID NO: 6. Even more preferred is a identity level of 85%, 90%, 92%, 94%, 95% 96%, 97%, 98%, 99% or even 100% in that order of preference.
Therefore, a preferred form of this embodiment relates to a 100/85 kD protein or an immunogenic fragment of said protein according to the invention wherein said protein or immunogenic fragment thereof has a sequence identity of at least 70%, preferably 75%, more preferably 80% or even 85%, 90%, 92%, preferably 94%, more preferably 95%, even more preferred 96%, 97%, 98%, 99% or even 100% in that order of preference identity with the amino acid sequence of SEQ ID NO: 6.
A most preferred form of this embodiment relates to a 100/85 kD protein or an immunogenic fragment of said protein, according to the invention as encoded by a nucleic acid sequence described in SEQ ID NO: 5.
A fourth embodiment of the present invention relates to a 79 kD protein or an immunogenic fragment thereof, said protein or immunogenic fragment thereof having an amino acid sequence that is at least 70% identical to the amino acid sequence as depicted in SEQ ID NO: 8.
Newly started cod production amounted to 605 tons only. However, given the fact that only in the UK, cod consumption is 170.000 tons yearly, and given the sharp reduction in European catch limits, it is clear that cod farming commercially becomes more and more attractive.
Louse infection as such is seldom the direct cause of illness and death, since sea lice feed primarily on mucus and skin. This however causes damage to both mucus and skin, making the host more vulnerable to opportunistic infections. These opportunistic infections thus are the direct cause of increasingly significant economic losses.
Classical treatment with organophosphate pesticides such as Nevugon and Aquagard is no longer an option. This is due to the fact that lice are developing an increasing resistance to such pesticides, and to the fact that such pesticides are no longer acceptable from an environmental point of view.
Therefore, vaccines against sea lice are highly desirable. Up till now, however, no such vaccines are on the market.
The search for suitable vaccine candidates has been going on for many years already.
This approach has however so far not led to vaccines for combating sea lice infection.
It is an objective of the present invention to provide a novel vaccine that is capable of inducing in susceptible fish such as i.a. Salmo salar, Salmo trutta and cod, a degree of protection against sea lice infection and to the effects of the infection.
Surprisingly it was found now, that several proteins could be isolated from the eggs of adult egg producing sea lice, more specifically Lepeophtheirus salmonis, Caligus rogercresseyi, Caligus elongatus and Caligus curtus, that are capable of inducing antibodies in Salmo salar, Salmo trutta and cod to the extent that fish vaccinated with these proteins are to an efficient degree protected against sea lice infection and the effects thereof.
Even more surprisingly, a strong cross-reactivity between antibodies against the 200 kD protein, the 180 kD protein, the 100/85 kD protein and the 79 kD protein respectively of one species and the homologous 200 kD protein, the 180 kD
protein, the 100/85 kD protein and the 79 kD protein in other species appered to exist.
Antibodies raised against this 200 kD protein, the 180 kD protein, the 100/85 kD
protein and the 79 kD protein from e.g. Lepeophtheirus salmonis additionally appeared to react strongly in a Western blot with homologous proteins from Caligus curtus and Caligus rogercresseyi.
As will be further clarified below, a first embodiment of the present invention relates to this 200 kD protein.
A second embodiment of the present invention relates to this 180 kD protein.
A third embodiment of the present invention relates to this 100/85 kD protein.
A fourth embodiment of the present invention relates to this 79 kD protein.
It is well-known in the art, that many different nucleic acid sequences can encode one and the same protein. This phenomenon is commonly known as wobble in the second and especially the third base of each triplet encoding an amino acid. This phenomenon can result in a heterology of about 30% for two nucleic acid sequences still encoding the same protein. Therefore, two nucleic acid sequences having an overall sequence identity as low as 70 % can still encode one and the same protein.
It will also be understood that, for the particular proteins embraced herein, natural variations can exist between individual sea lice strains. These variations may be demonstrated by (an) amino acid difference(s) in the overall sequence or by deletions, substitutions, insertions, inversions or additions of (an) amino acid(s) in said sequence. Amino acid substitutions which do not essentially alter biological and immunological activities, have been described, e.g. by Neurath et al. in "The Proteins"
Academic Press New York (1979). Amino acid replacements between related amino acids or replacements which have occurred frequently in evolution are, inter alia, Ser/Ala, Ser/Gly, Asp/Gly, Asp/Asn, Ile/Val (see Dayhof, M.D., Atlas of protein sequence and structure, Nat. Biomed. Res. Found., Washington D.C., 1978, vol.
5, suppl. 3). Other amino acid substitutions include Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Thr/Phe, Ala/Pro, Lys/Arg, Leu/Ile, Leu/Val and Ala/Glu.
Based on this information, Lipman and Pearson developed a method for rapid and sensitive protein comparison (Science,227, 1435-1441, 1985) and determining the functional similarity between identical proteins. Such amino acid substitutions of the exemplary embodiments of this invention, as well as variations having deletions and/or insertions are within the scope of the invention as long as the resulting proteins retain their immune reactivity. This explains why sea lice proteins according to the invention, when isolated from different field isolates, may have identity levels of about 70%, while still representing the same protein with the same immunological characteristics.
Those variations in the amino acid sequence of a certain protein according to the invention that still provide a protein capable of inducing an immune response against infection with sea lice or at least against the clinical manifestations of the infection are considered as "not essentially influencing the immunological characteristics".
Therefore, the protein according to the invention comprises those proteins and immunogenic fragments thereof that have an amino acid sequence that is at least 70%
identical to the amino acid sequence of the 200 kD protein as depicted in SEQ
ID NO:
2, the 180 kD protein as depicted in SEQ ID NO: 4, the 100/85kD protein as depicted in SEQ ID NO: 6 or the 79 kD protein as depicted in SEQ ID NO: 8.
Thus, one embodiment of the present invention relates to a 200 kD protein or an immunogenic fragment thereof, said protein or immunogenic fragment thereof having an amino acid sequence that is at least 70% identical to the amino acid sequence as depicted in SEQ ID NO: 2.
An immunogenic fragment is a fragment that has a length of at least 50 amino acids.
The concept of immunogenic fragments will be defined below.
Preferably, the amino acid sequence of a 200 kD protein or an immunogenic fragment of that protein has at least 75%, or more preferably 80% identity with the amino acid sequence of SEQ ID NO: 2. Even more preferred is a identity level of 85%, 90%, 92%, 94%, 95% 96%, 97%, 98%, 99% or even 100% in that order of preference.
Therefore, a preferred form of this embodiment relates to a 200 kD protein or an immunogenic fragment of said protein according to the invention wherein said protein or immunogenic fragment thereof has a sequence identity of at least 70%, preferably 75%, more preferably 80% or even 85%, 90%, 92%, preferably 94%, more preferably 95%, even more preferred 96%, 97%, 98%, 99% or even 100% in that order of preference identity with the amino acid sequence of SEQ ID NO: 2.
A most preferred form of this embodiment relates to a 200 kD protein or an 5 immunogenic fragment of said protein, according to the invention as encoded by a nucleic acid sequence described in SEQ ID NO: 1.
The level of protein identity can e.g. be determined with the computer program "BLAST 2 SEQUENCES" by selecting sub-program: "BLASTP", that can be found at www.ncbi.nlm.nih.l!ov/blast/bl2seg/b12.htm1.
A reference for this program is Tatiana A. Tatusova, Thomas L. Madden FEMS
Microbiol. Letters 174: 247-250 (1999). Matrix used: "blosum62". Parameters used are the default parameters:
Open gap: 11. Extension gap: 1. Gap x_dropoff: 50.
Amino acid sequences that comprise tandem arrays of the sequences according to the invention are also within the scope of the invention.
A second embodiment of the present invention relates to a 180 kD protein or an immunogenic fragment thereof, said protein or immunogenic fragment thereof having an amino acid sequence that is at least 70% identical to the amino acid sequence as depicted in SEQ ID NO: 4.
Preferably, the amino acid sequence of the 180 kD protein or an immunogenic fragment of that protein has at least 75%, or more preferably 80% identity with the amino acid sequence of SEQ ID NO: 4. Even more preferred is a identity level of 85%, 90%, 92%, 94%, 95% 96%, 97%, 98%, 99% or even 100% in that order of preference.
Therefore, a preferred form of this embodiment relates to a 180 kD protein or an immunogenic fragment of said protein according to the invention wherein said protein or immunogenic fragment thereof has a sequence identity of at least 70%, preferably 75%, more preferably 80% or even 85%, 90%, 92%, preferably 94%, more preferably 95%, even more preferred 96%, 97%, 98%, 99% or even 100% in that order of preference identity with the amino acid sequence of SEQ ID NO: 4.
A most preferred form of this embodiment relates to a 180 kD protein or an immunogenic fragment of said protein, according to the invention as encoded by a nucleic acid sequence described in SEQ ID NO: 3.
A third embodiment of the present invention relates to a 100/85 kD protein or an immunogenic fragment thereof, said protein or immunogenic fragment thereof having an amino acid sequence that is at least 70% identical to the amino acid sequence as depicted in SEQ ID NO: 6.
Preferably, the amino acid sequence of the 100/85 kD protein or an immunogenic fragment of that protein has at least 75%, or more preferably 80% identity with the amino acid sequence of SEQ ID NO: 6. Even more preferred is a identity level of 85%, 90%, 92%, 94%, 95% 96%, 97%, 98%, 99% or even 100% in that order of preference.
Therefore, a preferred form of this embodiment relates to a 100/85 kD protein or an immunogenic fragment of said protein according to the invention wherein said protein or immunogenic fragment thereof has a sequence identity of at least 70%, preferably 75%, more preferably 80% or even 85%, 90%, 92%, preferably 94%, more preferably 95%, even more preferred 96%, 97%, 98%, 99% or even 100% in that order of preference identity with the amino acid sequence of SEQ ID NO: 6.
A most preferred form of this embodiment relates to a 100/85 kD protein or an immunogenic fragment of said protein, according to the invention as encoded by a nucleic acid sequence described in SEQ ID NO: 5.
A fourth embodiment of the present invention relates to a 79 kD protein or an immunogenic fragment thereof, said protein or immunogenic fragment thereof having an amino acid sequence that is at least 70% identical to the amino acid sequence as depicted in SEQ ID NO: 8.
Preferably, the amino acid sequence of the 79 kD protein or an immunogenic fragment of that protein has at least 75%, or more preferably 80% identity with the amino acid sequence of SEQ ID NO: 8. Even more preferred is a identity level of 85%, 90%, 92%, 94%, 95% 96%, 97%, 98%, 99% or even 100% in that order of preference.
Therefore, a preferred form of this embodiment relates to a 79 kD protein or an immunogenic fragment of said protein according to the invention wherein said protein or immunogenic fragment thereof has a sequence identity of at least 70%, preferably 75%, more preferably 80% or even 85%, 90%, 92%, preferably 94%, more preferably 95%, even more preferred 96%, 97%, 98%, 99% or even 100% in that order of preference identity with the amino acid sequence of SEQ ID NO: 8.
A most preferred form of this embodiment relates to a 79 kD protein or an immunogenic fragment of said protein, according to the invention as encoded by a nucleic acid sequence described in SEQ ID NO: 7.
As an readily be seen from the Examples, antibodies raised against e.g. the 200 kD
protein, the 180 kD protein, the 100/85 kD protein or the 79 kD protein as isolated from L. salmonis react strongly in a Western blot with the homologous protein of e.g.
Caligus curtus or Caligus rogercresseyi. This already indicates that the epitopes against which the antibodies are directed, are well-conserved within the copepod ectoparasites.
Therefore, copepod ectoparasitic proteins from the eggs of adult egg producing sea lice that react in a Western blot with antiserum raised against a protein having the amino acid sequence as depicted in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 and SEQ ID NO: 8 are also considered to fall within the scope of the invention.
Specific examples of such ectoparasitic copepods are of course the species Lepeophtheirus salmonis, Caligus curtus, Caligus elongatus and Caligus rogercresseyi as mentioned above.
Since the nucleic acid sequences encoding the nove1200 kD protein, the 180 kD
protein, the 100/85 kD protein and the 79 kD protein according to the present invention are disclosed here, it is now feasible to obtain this protein in sufficient quantities. This can e.g. be done by using expression systems to express the whole or parts of the gene encoding the 200 kD protein, the 180 kD protein, the 100/85 kD
protein or the 79 kD protein. An essential requirement for the expression of the nucleic acid sequence is an adequate promoter functionally linked to the nucleic acid sequence, so that the nucleic acid sequence is under the control of the promoter. It is obvious to those skilled in the art that the choice of a promoter extends to any eukaryotic, prokaryotic or viral promoter capable of directing gene transcription in cells used as host cells for protein expression.
Functionally linked promoters are promoters that are capable of controlling the transcription of the nucleic acid sequences to which they are linked.
Constructs comprising the nucleic acid sequences encoding the 200 kD protein, the 180 kD protein, the 100/85 kD protein or the 79 kD protein according to the invention under the control of a functionally linked promoter will be further referred to as recombinant DNA molecules.
Such a promoter can be the native promoter of the protein gene or another promoter, provided that that promoter is functional in the cell used for expression. It can also be a heterologous promoter. When the host cells are bacteria, useful expression control sequences which may be used include the Trp promoter and operator (Goeddel, et al., Nucl. Acids Res., 8, 4057, 1980); the lac promoter and operator (Chang, et al., Nature, 275, 615, 1978); the outer membrane protein promoter (Nakamura, K. and Inouge, M., EMBO J., 1, 771-775, 1982); the bacteriophage lambda promoters and operators (Remaut, E. et al., Nucl. Acids Res., 11, 4677-4688, 1983); the a-amylase (B.
subtilis) promoter and operator, termination sequences and other expression enhancement and control sequences compatible with the selected host cell.
When the host cell is yeast, useful expression control sequences include, e.g., a-mating factor. For insect cells the polyhedrin or p10 promoters of baculoviruses can be used (Smith, G.E. et al., Mol. Cell. Biol. 3, 2156-65, 1983). When the host cell is of vertebrate origin illustrative useful expression control sequences include the (human) cytomegalovirus immediate early promoter (Seed, B. et al., Nature 329, 842, 1987; Fynan, E.F. et al., PNAS 90, 11478-11482,1993; Ulmer, J.B. et al., Science 259, 1745-1748, 1993), Rous sarcoma virus LTR (RSV, Gorman, C.M. et al., PNAS 79, 6777-6781, 1982; Fynan et al., supra; Ulmer et al., supra), the MPSV
LTR
Therefore, a preferred form of this embodiment relates to a 79 kD protein or an immunogenic fragment of said protein according to the invention wherein said protein or immunogenic fragment thereof has a sequence identity of at least 70%, preferably 75%, more preferably 80% or even 85%, 90%, 92%, preferably 94%, more preferably 95%, even more preferred 96%, 97%, 98%, 99% or even 100% in that order of preference identity with the amino acid sequence of SEQ ID NO: 8.
A most preferred form of this embodiment relates to a 79 kD protein or an immunogenic fragment of said protein, according to the invention as encoded by a nucleic acid sequence described in SEQ ID NO: 7.
As an readily be seen from the Examples, antibodies raised against e.g. the 200 kD
protein, the 180 kD protein, the 100/85 kD protein or the 79 kD protein as isolated from L. salmonis react strongly in a Western blot with the homologous protein of e.g.
Caligus curtus or Caligus rogercresseyi. This already indicates that the epitopes against which the antibodies are directed, are well-conserved within the copepod ectoparasites.
Therefore, copepod ectoparasitic proteins from the eggs of adult egg producing sea lice that react in a Western blot with antiserum raised against a protein having the amino acid sequence as depicted in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 and SEQ ID NO: 8 are also considered to fall within the scope of the invention.
Specific examples of such ectoparasitic copepods are of course the species Lepeophtheirus salmonis, Caligus curtus, Caligus elongatus and Caligus rogercresseyi as mentioned above.
Since the nucleic acid sequences encoding the nove1200 kD protein, the 180 kD
protein, the 100/85 kD protein and the 79 kD protein according to the present invention are disclosed here, it is now feasible to obtain this protein in sufficient quantities. This can e.g. be done by using expression systems to express the whole or parts of the gene encoding the 200 kD protein, the 180 kD protein, the 100/85 kD
protein or the 79 kD protein. An essential requirement for the expression of the nucleic acid sequence is an adequate promoter functionally linked to the nucleic acid sequence, so that the nucleic acid sequence is under the control of the promoter. It is obvious to those skilled in the art that the choice of a promoter extends to any eukaryotic, prokaryotic or viral promoter capable of directing gene transcription in cells used as host cells for protein expression.
Functionally linked promoters are promoters that are capable of controlling the transcription of the nucleic acid sequences to which they are linked.
Constructs comprising the nucleic acid sequences encoding the 200 kD protein, the 180 kD protein, the 100/85 kD protein or the 79 kD protein according to the invention under the control of a functionally linked promoter will be further referred to as recombinant DNA molecules.
Such a promoter can be the native promoter of the protein gene or another promoter, provided that that promoter is functional in the cell used for expression. It can also be a heterologous promoter. When the host cells are bacteria, useful expression control sequences which may be used include the Trp promoter and operator (Goeddel, et al., Nucl. Acids Res., 8, 4057, 1980); the lac promoter and operator (Chang, et al., Nature, 275, 615, 1978); the outer membrane protein promoter (Nakamura, K. and Inouge, M., EMBO J., 1, 771-775, 1982); the bacteriophage lambda promoters and operators (Remaut, E. et al., Nucl. Acids Res., 11, 4677-4688, 1983); the a-amylase (B.
subtilis) promoter and operator, termination sequences and other expression enhancement and control sequences compatible with the selected host cell.
When the host cell is yeast, useful expression control sequences include, e.g., a-mating factor. For insect cells the polyhedrin or p10 promoters of baculoviruses can be used (Smith, G.E. et al., Mol. Cell. Biol. 3, 2156-65, 1983). When the host cell is of vertebrate origin illustrative useful expression control sequences include the (human) cytomegalovirus immediate early promoter (Seed, B. et al., Nature 329, 842, 1987; Fynan, E.F. et al., PNAS 90, 11478-11482,1993; Ulmer, J.B. et al., Science 259, 1745-1748, 1993), Rous sarcoma virus LTR (RSV, Gorman, C.M. et al., PNAS 79, 6777-6781, 1982; Fynan et al., supra; Ulmer et al., supra), the MPSV
LTR
(Stacey et al., J. Virology 50, 725-732, 1984), SV40 immediate early promoter (Sprague J. et al., J. Virology 45, 773 ,1983), the SV-40 promoter (Berman, P.W. et al., Science, 222, 524-527, 1983), the metallothionein promoter (Brinster, R.L. et al., Nature 296, 39-42, 1982), the heat shock promoter (Voellmy et al., Proc. Natl.
Acad.
Sci. USA, 82, 4949-53, 1985), the major late promoter of Ad2 and the (3-actin promoter (Tang et al., Nature 356, 152-154, 1992). The regulatory sequences may also include terminator and poly-adenylation sequences. Amongst the sequences that can be used are the well known bovine growth hormone poly-adenylation sequence, the SV40 poly-adenylation sequence, the human cytomegalovirus (hCMV) terminator and poly-adenylation sequences.
Bacterial, yeast, fungal, insect and vertebrate cell expression systems are very frequently used systems. Such systems are well-known in the art and generally available, e.g. commercially through Clontech Laboratories, Inc. 4030 Fabian Way, Palo Alto, California 94303-4607, USA. Next to these expression systems, parasite-based expression systems are attractive expression systems. Such systems are e.g.
described in the French Patent Application with Publication number 2 714 074, and in US NTIS Publication No US 08/043109 (Hoffman, S. and Rogers, W.: Public. Date December 1993).
In view of this, another embodiment of the invention relates to Live Recombinant Carriers (LRCs) comprising a nucleic acid sequence encoding the 200 kD
protein, the 180 kD protein, the 100/85 kD protein or the 79 kD protein or an immunogenic part of any of said proteins. Preferably, the LRC comprises a DNA fragment that in turn comprises a nucleic acid sequence encoding the 200 kD protein, a 180 kD
protein, a 100/85 kD protein or a 79 kD protein according to the invention or an immunogenic part thereof. More preferably, the nucleic acid sequence encoding the 200 kD
protein, the 180 kD protein, the 100/85 kD protein or the 79 kD protein or an immunogenic part of any of said proteins is brought under the control of a functionally linked promoter. These LRCs are micro-organisms or viruses in which additional genetic information, in this case a nucleic acid sequence encoding the 200 kD protein, the 180 kD protein, the 100/85 kD protein or the 79 kD protein, or an immunogenic fragment of any of said proteins as described above has been cloned. Fish infected with such LRCs will produce an immunological response not only against the immunogens of the carrier, but also against the immunogenic parts of the protein(s) for which the genetic code is additionally cloned into the LRC, e.g. the 200 kD protein, the 180 kD
protein, the 100/85 kD protein or the 79 kD protein described in the invention.
5 As an example of bacterial LRCs, bacteria such as Vibrio anguillarum known in the art can attractively be used. (Singer, J.T. et al., New Developments in Marine Biotechnology, p. 303-306, Eds. Le Gal and Halvorson, Plenum Press, New York, 1998).
Acad.
Sci. USA, 82, 4949-53, 1985), the major late promoter of Ad2 and the (3-actin promoter (Tang et al., Nature 356, 152-154, 1992). The regulatory sequences may also include terminator and poly-adenylation sequences. Amongst the sequences that can be used are the well known bovine growth hormone poly-adenylation sequence, the SV40 poly-adenylation sequence, the human cytomegalovirus (hCMV) terminator and poly-adenylation sequences.
Bacterial, yeast, fungal, insect and vertebrate cell expression systems are very frequently used systems. Such systems are well-known in the art and generally available, e.g. commercially through Clontech Laboratories, Inc. 4030 Fabian Way, Palo Alto, California 94303-4607, USA. Next to these expression systems, parasite-based expression systems are attractive expression systems. Such systems are e.g.
described in the French Patent Application with Publication number 2 714 074, and in US NTIS Publication No US 08/043109 (Hoffman, S. and Rogers, W.: Public. Date December 1993).
In view of this, another embodiment of the invention relates to Live Recombinant Carriers (LRCs) comprising a nucleic acid sequence encoding the 200 kD
protein, the 180 kD protein, the 100/85 kD protein or the 79 kD protein or an immunogenic part of any of said proteins. Preferably, the LRC comprises a DNA fragment that in turn comprises a nucleic acid sequence encoding the 200 kD protein, a 180 kD
protein, a 100/85 kD protein or a 79 kD protein according to the invention or an immunogenic part thereof. More preferably, the nucleic acid sequence encoding the 200 kD
protein, the 180 kD protein, the 100/85 kD protein or the 79 kD protein or an immunogenic part of any of said proteins is brought under the control of a functionally linked promoter. These LRCs are micro-organisms or viruses in which additional genetic information, in this case a nucleic acid sequence encoding the 200 kD protein, the 180 kD protein, the 100/85 kD protein or the 79 kD protein, or an immunogenic fragment of any of said proteins as described above has been cloned. Fish infected with such LRCs will produce an immunological response not only against the immunogens of the carrier, but also against the immunogenic parts of the protein(s) for which the genetic code is additionally cloned into the LRC, e.g. the 200 kD protein, the 180 kD
protein, the 100/85 kD protein or the 79 kD protein described in the invention.
5 As an example of bacterial LRCs, bacteria such as Vibrio anguillarum known in the art can attractively be used. (Singer, J.T. et al., New Developments in Marine Biotechnology, p. 303-306, Eds. Le Gal and Halvorson, Plenum Press, New York, 1998).
10 Also, LRC viruses may be used as a way of transporting the nucleic acid sequence into a target cell. Viruses suitable for this task are e.g. alphavirus-vectors. A review on alphavirus-vectors is given by Sondra Schlesinger and Thomas W. Dubensky Jr., Current opinion in Biotechnology, 10:434-439 (1999).
Preferred viral LRC's are viruses from the genus Novirhabdoviruses, especially the species viral hemorrhagic septicemia virus, and infectious hematopoietic necrosis virus (IHNV). For instance IHNV is a fish pathogen, for which an attenuated viral expression and delivery system for use in salmonids has been described. (WO
03/097090; Biacchesi et al., 2000, J. of Virol., vol. 74, p. 11247-11253).
Deletion of the viral NV protein attenuates the virus and creates room for insertion of a foreign gene. A preferred construct is a recombinant IHNV carrying a nucleic acid construct capable of encoding a polypeptide or protein according to the invention. Such an LRC
is then administered to target fish for instance by immersion vaccination The technique of in vivo homologous recombination, well-known in the art, can be used to introduce a recombinant nucleic acid sequence into the genome of a bacterium, parasite or virus of choice, capable of inducing expression of the inserted nucleic acid sequence according to the invention in the host animal.
Finally another form of this embodiment of the invention relates to a host cell comprising a recombinant DNA molecule or a live recombinant carrier as described above.
A host cell may be a cell of bacterial origin, e.g. Escherichia coli, Bacillus subtilis and Lactobacillus species, in combination with bacteria-based plasmids as pBR322, or bacterial expression vectors as pGEX, or with bacteriophages. The host cell may also be of eukaryotic origin, e.g. yeast-cells in combination with yeast-specific vector molecules, or higher eukaryotic cells like insect cells (Luckow et al; Bio-technology 6: 47-55 (1988)) in combination with vectors or recombinant baculoviruses, plant cells in combination with e.g. Ti-plasmid based vectors or plant viral vectors (Barton, K.A. et al; Ce1132: 1033 (1983), mammalian cells like Hela cells, Chinese Hamster Ovary cells (CHO) or Crandell Feline Kidney-cells, also with appropriate vectors or recombinant viruses.
As is mentioned above, it is one of the merits of the present invention that it was found that the 200 kD protein, the 180 kD protein, the 100/85 kD protein and the 79 kD protein each induce a degree of protection against sea lice species.
Therefore, the 200 kD protein, the 180 kD protein, the 100/85 kD protein and the 79 kD
protein each constitute a major compound of a vaccine for the protection of fish against fish sea lice species. Therefore, another embodiment relates to vaccines for combating sea lice infection, comprising at least one or, preferably, more of these proteins.
When a protein is used for vaccination purposes or for raising antibodies, it is not necessary to use the whole protein. It is also possible to use a fragment of that protein that is capable, as such or coupled to a carrier such as e.g. KLH, of inducing an immune response against that protein, a so-called immunogenic fragment. An "immunogenic fragment" is understood to be a fragment of the full-length protein that still has retained its capability to induce an immune response in a vertebrate host, i.e.
comprises a B- or T-cell epitope. Shortly, an immunogenic fragment is a fragment that is capable of inducing antibodies that react with the full length protein, i.e. the 200 kD
protein, the 180 kD protein, the 100/85 kD protein or the 79 D protein according to the invention. At this moment, a variety of techniques is available to easily identify DNA fragments encoding immunogenic fragments (determinants). The method described by Geysen et al (Patent Application WO 84/03564, Patent Application WO
86/06487, US Patent NR. 4,833,092, Proc. Natl Acad. Sci. 81: 3998-4002 (1984), J.
Imm. Meth. 102, 259-274 (1987), the so-called PEPSCAN method is an easy to perform, quick and well-established method for the detection of epitopes; the immunologically important regions of the protein. The method is used world-wide and as such well-known to man skilled in the art. This (empirical) method is especially suitable for the detection of B-cell epitopes. Also, given the sequence of the gene encoding any protein, computer algorithms are able to designate specific protein fragments as the immunologically important epitopes on the basis of their sequential and/or structural agreement with epitopes that are now known. The determination of these regions is based on a combination of the hydrophilicity criteria according to Hopp and Woods (Proc. Natl. Acad. Sci. 78: 38248-3828 (1981)), and the secondary structure aspects according to Chou and Fasman (Advances in Enzymology 47: 45-148 (1987) and US Patent 4,554,101). T-cell epitopes can likewise be predicted from the sequence by computer with the aid of Berzofsky's amphiphilicity criterion (Science 235, 1059-1062 (1987) and US Patent application NTIS US 07/005,885).
A
condensed overview is found in: Shan Lu on common principles: Tibtech 9: 238-(1991), Good et al on Malaria epitopes; Science 235: 1059-1062 (1987), Lu for a review; Vaccine 10: 3-7 (1992), Berzofsky for HIV-epitopes; The FASEB Journal 5:2412-2418 (1991).
Thus, one form of this embodiment of the invention relates to vaccines for combating sea lice infection, that comprise a 200 kD protein, a 180 kD protein, a 100/85 kD
protein or a 79 kD protein according to the invention or an immunogenic fragment of any of said proteins as described above, together with a pharmaceutically acceptable carrier.
Still another embodiment relates to the use of a 200 kD protein, a 180 kD
protein, a 100/85 kD protein or a 79 kD protein according to the invention or an immunogenic fragment of any of said proteins for the manufacturing of a vaccine for combating sea louse infections.
Vaccines based upon the 200 kD protein, the 180 kD protein, the 100/85 kD
protein or the 79 kD protein, or an immunogenic fragment of any of said proteins can easily be made by admixing the protein or immunogenic fragments thereof with a pharmaceutically acceptable carrier as described below.
Another possibility for such vaccines is a vaccine comprising a host cell as described above, and a pharmaceutically acceptable carrier.
Alternatively, a vaccine according to the invention can comprise live recombinant carriers as described above, capable of expressing the protein according to the invention or immunogenic fragments thereof. Such vaccines, e.g. based upon a Vibrio carrier or a viral carrier e.g. an alphavirus vector have the advantage over subunit vaccines that they better mimic the natural way of infection of sea lice.
Moreover, their self-propagation is an advantage since only low amounts of the recombinant carrier are necessary for immunization.
All vaccines described above contribute to active vaccination, i.e. they trigger the host's defense system. Alternatively, antibodies can be raised in e.g. rabbits or can be obtained from antibody-producing cell lines as described below. Such antibodies can then be administered to the fish. This method of vaccination, passive vaccination, is the vaccination of choice when an animal is already infected, and there is no time to allow the natural immune response to be triggered. It is also the preferred method for vaccinating animals that are prone to sudden high infection pressure. The administered antibodies against the 200 kD protein, the 180 kD protein, the 100/85 kD
protein or the 79 kD protein according to the invention or immunogenic fragments thereof can in these cases bind directly to the protein of the sea lice. This has the advantage that it decreases the load of the sea lice infection.
Therefore, one other form of this embodiment of the invention relates to a vaccine for combating sea lice infection that comprises antibodies against the 200 kD
protein, the 180 kD protein, the 100/85 kD protein or the 79 kD protein, or an immunogenic fragment of any of said proteins, and a pharmaceutically acceptable carrier.
The proteins or immunogenic fragments thereof, e.g. expressed as indicated above can be used to produce antibodies, which may be polyclonal, monospecific or monoclonal (or derivatives thereof). If polyclonal antibodies are desired, techniques for producing and processing polyclonal sera are well-known in the art (e.g. Mayer and Walter, eds.
Immunochemical Methods in Cell and Molecular Biology, Academic Press, London, 1987).
Monoclonal antibodies, reactive against the protein according to the invention or an immunogenic fragment thereof according to the present invention, can be prepared by immunizing inbred mice by techniques also known in the art (Kohler and Milstein, Nature, 256, 495-497, 1975).
Preferred viral LRC's are viruses from the genus Novirhabdoviruses, especially the species viral hemorrhagic septicemia virus, and infectious hematopoietic necrosis virus (IHNV). For instance IHNV is a fish pathogen, for which an attenuated viral expression and delivery system for use in salmonids has been described. (WO
03/097090; Biacchesi et al., 2000, J. of Virol., vol. 74, p. 11247-11253).
Deletion of the viral NV protein attenuates the virus and creates room for insertion of a foreign gene. A preferred construct is a recombinant IHNV carrying a nucleic acid construct capable of encoding a polypeptide or protein according to the invention. Such an LRC
is then administered to target fish for instance by immersion vaccination The technique of in vivo homologous recombination, well-known in the art, can be used to introduce a recombinant nucleic acid sequence into the genome of a bacterium, parasite or virus of choice, capable of inducing expression of the inserted nucleic acid sequence according to the invention in the host animal.
Finally another form of this embodiment of the invention relates to a host cell comprising a recombinant DNA molecule or a live recombinant carrier as described above.
A host cell may be a cell of bacterial origin, e.g. Escherichia coli, Bacillus subtilis and Lactobacillus species, in combination with bacteria-based plasmids as pBR322, or bacterial expression vectors as pGEX, or with bacteriophages. The host cell may also be of eukaryotic origin, e.g. yeast-cells in combination with yeast-specific vector molecules, or higher eukaryotic cells like insect cells (Luckow et al; Bio-technology 6: 47-55 (1988)) in combination with vectors or recombinant baculoviruses, plant cells in combination with e.g. Ti-plasmid based vectors or plant viral vectors (Barton, K.A. et al; Ce1132: 1033 (1983), mammalian cells like Hela cells, Chinese Hamster Ovary cells (CHO) or Crandell Feline Kidney-cells, also with appropriate vectors or recombinant viruses.
As is mentioned above, it is one of the merits of the present invention that it was found that the 200 kD protein, the 180 kD protein, the 100/85 kD protein and the 79 kD protein each induce a degree of protection against sea lice species.
Therefore, the 200 kD protein, the 180 kD protein, the 100/85 kD protein and the 79 kD
protein each constitute a major compound of a vaccine for the protection of fish against fish sea lice species. Therefore, another embodiment relates to vaccines for combating sea lice infection, comprising at least one or, preferably, more of these proteins.
When a protein is used for vaccination purposes or for raising antibodies, it is not necessary to use the whole protein. It is also possible to use a fragment of that protein that is capable, as such or coupled to a carrier such as e.g. KLH, of inducing an immune response against that protein, a so-called immunogenic fragment. An "immunogenic fragment" is understood to be a fragment of the full-length protein that still has retained its capability to induce an immune response in a vertebrate host, i.e.
comprises a B- or T-cell epitope. Shortly, an immunogenic fragment is a fragment that is capable of inducing antibodies that react with the full length protein, i.e. the 200 kD
protein, the 180 kD protein, the 100/85 kD protein or the 79 D protein according to the invention. At this moment, a variety of techniques is available to easily identify DNA fragments encoding immunogenic fragments (determinants). The method described by Geysen et al (Patent Application WO 84/03564, Patent Application WO
86/06487, US Patent NR. 4,833,092, Proc. Natl Acad. Sci. 81: 3998-4002 (1984), J.
Imm. Meth. 102, 259-274 (1987), the so-called PEPSCAN method is an easy to perform, quick and well-established method for the detection of epitopes; the immunologically important regions of the protein. The method is used world-wide and as such well-known to man skilled in the art. This (empirical) method is especially suitable for the detection of B-cell epitopes. Also, given the sequence of the gene encoding any protein, computer algorithms are able to designate specific protein fragments as the immunologically important epitopes on the basis of their sequential and/or structural agreement with epitopes that are now known. The determination of these regions is based on a combination of the hydrophilicity criteria according to Hopp and Woods (Proc. Natl. Acad. Sci. 78: 38248-3828 (1981)), and the secondary structure aspects according to Chou and Fasman (Advances in Enzymology 47: 45-148 (1987) and US Patent 4,554,101). T-cell epitopes can likewise be predicted from the sequence by computer with the aid of Berzofsky's amphiphilicity criterion (Science 235, 1059-1062 (1987) and US Patent application NTIS US 07/005,885).
A
condensed overview is found in: Shan Lu on common principles: Tibtech 9: 238-(1991), Good et al on Malaria epitopes; Science 235: 1059-1062 (1987), Lu for a review; Vaccine 10: 3-7 (1992), Berzofsky for HIV-epitopes; The FASEB Journal 5:2412-2418 (1991).
Thus, one form of this embodiment of the invention relates to vaccines for combating sea lice infection, that comprise a 200 kD protein, a 180 kD protein, a 100/85 kD
protein or a 79 kD protein according to the invention or an immunogenic fragment of any of said proteins as described above, together with a pharmaceutically acceptable carrier.
Still another embodiment relates to the use of a 200 kD protein, a 180 kD
protein, a 100/85 kD protein or a 79 kD protein according to the invention or an immunogenic fragment of any of said proteins for the manufacturing of a vaccine for combating sea louse infections.
Vaccines based upon the 200 kD protein, the 180 kD protein, the 100/85 kD
protein or the 79 kD protein, or an immunogenic fragment of any of said proteins can easily be made by admixing the protein or immunogenic fragments thereof with a pharmaceutically acceptable carrier as described below.
Another possibility for such vaccines is a vaccine comprising a host cell as described above, and a pharmaceutically acceptable carrier.
Alternatively, a vaccine according to the invention can comprise live recombinant carriers as described above, capable of expressing the protein according to the invention or immunogenic fragments thereof. Such vaccines, e.g. based upon a Vibrio carrier or a viral carrier e.g. an alphavirus vector have the advantage over subunit vaccines that they better mimic the natural way of infection of sea lice.
Moreover, their self-propagation is an advantage since only low amounts of the recombinant carrier are necessary for immunization.
All vaccines described above contribute to active vaccination, i.e. they trigger the host's defense system. Alternatively, antibodies can be raised in e.g. rabbits or can be obtained from antibody-producing cell lines as described below. Such antibodies can then be administered to the fish. This method of vaccination, passive vaccination, is the vaccination of choice when an animal is already infected, and there is no time to allow the natural immune response to be triggered. It is also the preferred method for vaccinating animals that are prone to sudden high infection pressure. The administered antibodies against the 200 kD protein, the 180 kD protein, the 100/85 kD
protein or the 79 kD protein according to the invention or immunogenic fragments thereof can in these cases bind directly to the protein of the sea lice. This has the advantage that it decreases the load of the sea lice infection.
Therefore, one other form of this embodiment of the invention relates to a vaccine for combating sea lice infection that comprises antibodies against the 200 kD
protein, the 180 kD protein, the 100/85 kD protein or the 79 kD protein, or an immunogenic fragment of any of said proteins, and a pharmaceutically acceptable carrier.
The proteins or immunogenic fragments thereof, e.g. expressed as indicated above can be used to produce antibodies, which may be polyclonal, monospecific or monoclonal (or derivatives thereof). If polyclonal antibodies are desired, techniques for producing and processing polyclonal sera are well-known in the art (e.g. Mayer and Walter, eds.
Immunochemical Methods in Cell and Molecular Biology, Academic Press, London, 1987).
Monoclonal antibodies, reactive against the protein according to the invention or an immunogenic fragment thereof according to the present invention, can be prepared by immunizing inbred mice by techniques also known in the art (Kohler and Milstein, Nature, 256, 495-497, 1975).
Still another embodiment of this invention relates to antibodies against the sea lice protein described in the invention or against an immunogenic fragment of that protein.
Methods for large-scale production of antibodies according to the invention are also known in the art. Such methods rely on the cloning of (fragments of) the genetic information encoding the protein according to the invention in a filamentous phage for phage display. Such techniques are described i.a. at the "Antibody Engineering Page" under "filamentous phage display" at htt ://axinitl.init.u.ni-~'narburg.de/--rekJae ~hage.htrr~l., and in review papers by Cortese, R. et al., (1994) in Trends Biotechn. 12: 262-267., by Clackson, T. & Wells, J.A. (1994) in Trends Biotechn. 12: 173-183, by Marks, J.D. et al., (1992) in J. Biol. Chem. 267:
16010, by Winter, G. et al., (1994) in Annu. Rev. Immunol. 12: 433-455, and by Little, M. et al., (1994) Biotechn. Adv. 12: 539-555. The phages are subsequently used to screen camelid expression libraries expressing camelid heavy chain antibodies. (Muyldermans, S. and Lauwereys, M., Journ. Molec. Recogn. 12: 131-(1999) and Ghahroudi, M.A. et al., FEBS Letters 414: 512-526 (1997)). Cells from the library that express the desired antibodies can be replicated and subsequently be used for large scale expression of antibodies.
Still another embodiment relates to a method for the preparation of a vaccine according to the invention that comprises the admixing of antibodies according to the invention and a pharmaceutically acceptable carrier.
An alternative and efficient way of vaccination is direct vaccination with DNA
encoding the relevant antigen. Direct vaccination with DNA encoding proteins has been successful for many different proteins. (As reviewed in e.g. Donnelly et al., The Immunologist 2: 20-26 (1993)). This way of vaccination is also attractive for the vaccination of fish against sea lice infection. Therefore, still other forms of the vaccine embodiment of the invention relate to vaccines comprising nucleic acid sequences encoding a protein according to the invention or immunogenic fragments thereof, to vaccines comprising DNA fragments that comprise such nucleic acid sequences and to recombinant DNA molecules comprising such nucleic acid sequences.
Examples of DNA fragments that are suitable for use in a DNA vaccine according to the invention are conventional cloning or expression plasmids for bacterial, eukaryotic and yeast host cells, many of said plasmids being commercially available. Well-known examples of such plasmids are pBR322 and pcDNA3 (Invitrogen). The DNA
5 fragments or recombinant DNA molecules should be able to induce protein expression of the nucleic acid sequences. The DNA fragments or recombinant DNA molecules may comprise one or more protein-encoding nucleic acid sequences. In addition, the DNA fragments or recombinant DNA molecules may comprise other nucleic acid sequences such as the immune-stimulating oligonucleotides having unmethylated 10 CpG di-nucleotides, or nucleic acid sequences that code for other antigenic proteins or adjuvating cytokines.
Thus, both in view of their use in expression systems and their use in DNA
vaccination, another embodiment of the invention relates to nucleic acid sequences 15 encoding an 200 kD protein or an immunogenic fragment of that protein comprising a nucleic acid sequence that has a identity of at least 70%, preferably 75%, more preferably 80% or even 85%, 90%, 92%, preferably 94%, more preferably 95%, even more preferred 96%, 97%, 98%, 99% or even 100% in that order of preference identity with the the nucleic acid sequence depicted in SEQ ID NO: 1.
The percentage of identity between any nucleic acid and a nucleic acid according to the invention can be determined with the computer program "BLAST 2 SEQUENCES" by selecting sub-program: "BlastN" (T. Tatusova & T. Madden, 1999, FEMS Microbiol. Letters, vol. 174, p. 247-250), that can be found at the internet address www.ncbi.nlm.nih.gov/blast/bl2seq/b12.htm1. Parameters that are to be used are the default parameters: reward for a match: +l; penalty for a mismatch: -2; open gap penalty: 5; extension gap penalty: 2; and gap x_dropoff: 50.
Unlike the output of the BlastP program described above, the BlastN program does not list similarities, only identities: the percentage of nucleotides that are identical is indicated as "Identities".
Next to using computer algorithms for determining the level of identity/mismatch between any nucleic acid and a nucleic acid according to the invention, experimental techniques can also be used. Especially by hybridisation under conditions of controlled stringency.
The definition of stringent hybridisation conditions, as a function of the identity between two nucleotide sequences, follows from the formula for the melting temperature Tm of Meinkoth and Wahl (1984, Anal. Biochem., vol. 138, p. 267-284):
Tm =[81.5 C + 16.6(log M) + 0.41(%GC) - 0.61(%formamide) - 500/L] - 1 C/1%
mismatch In this formula: M is the molarity of monovalent cations; %GC is the percentage of guanosine and cytosine nucleotides in the DNA; L is the length of the hybrid in base pairs; and "mismatch" is the lack of an identical match.
Washing conditions subsequent to the hybridization can also be made more or less stringent, thereby selecting for higher or lower percentages of identity respectively.
In general, higher stringency is obtained by reducing the salt concentration, and increasing the incubation temperature. It is well within the capacity of the skilled person to select hybridisation conditions that match a certain percentage-level of identity as determined by computer analysis.
Merely as an example, and of course depending upon the G/C content and the length of the fragment: "stringent" washing conditions are conditions of 1 x SSC, 0.1% SDS
at a temperature of 65 C; highly stringent conditions refer to a reduction in SSC
concentration towards 0.3 x SSC.
Another embodiment of the invention relates to nucleic acid sequences encoding an 180 kD protein or an immunogenic fragment of that protein comprising a nucleic acid sequence that has a identity of at least 70%, preferably 75%, more preferably 80% or even 85%, 90%, 92%, preferably 94%, more preferably 95%, even more preferred 96%, 97%, 98%, 99% or even 100% in that order of preference identity with the the nucleic acid sequence depicted in SEQ ID NO: 3.
Methods for large-scale production of antibodies according to the invention are also known in the art. Such methods rely on the cloning of (fragments of) the genetic information encoding the protein according to the invention in a filamentous phage for phage display. Such techniques are described i.a. at the "Antibody Engineering Page" under "filamentous phage display" at htt ://axinitl.init.u.ni-~'narburg.de/--rekJae ~hage.htrr~l., and in review papers by Cortese, R. et al., (1994) in Trends Biotechn. 12: 262-267., by Clackson, T. & Wells, J.A. (1994) in Trends Biotechn. 12: 173-183, by Marks, J.D. et al., (1992) in J. Biol. Chem. 267:
16010, by Winter, G. et al., (1994) in Annu. Rev. Immunol. 12: 433-455, and by Little, M. et al., (1994) Biotechn. Adv. 12: 539-555. The phages are subsequently used to screen camelid expression libraries expressing camelid heavy chain antibodies. (Muyldermans, S. and Lauwereys, M., Journ. Molec. Recogn. 12: 131-(1999) and Ghahroudi, M.A. et al., FEBS Letters 414: 512-526 (1997)). Cells from the library that express the desired antibodies can be replicated and subsequently be used for large scale expression of antibodies.
Still another embodiment relates to a method for the preparation of a vaccine according to the invention that comprises the admixing of antibodies according to the invention and a pharmaceutically acceptable carrier.
An alternative and efficient way of vaccination is direct vaccination with DNA
encoding the relevant antigen. Direct vaccination with DNA encoding proteins has been successful for many different proteins. (As reviewed in e.g. Donnelly et al., The Immunologist 2: 20-26 (1993)). This way of vaccination is also attractive for the vaccination of fish against sea lice infection. Therefore, still other forms of the vaccine embodiment of the invention relate to vaccines comprising nucleic acid sequences encoding a protein according to the invention or immunogenic fragments thereof, to vaccines comprising DNA fragments that comprise such nucleic acid sequences and to recombinant DNA molecules comprising such nucleic acid sequences.
Examples of DNA fragments that are suitable for use in a DNA vaccine according to the invention are conventional cloning or expression plasmids for bacterial, eukaryotic and yeast host cells, many of said plasmids being commercially available. Well-known examples of such plasmids are pBR322 and pcDNA3 (Invitrogen). The DNA
5 fragments or recombinant DNA molecules should be able to induce protein expression of the nucleic acid sequences. The DNA fragments or recombinant DNA molecules may comprise one or more protein-encoding nucleic acid sequences. In addition, the DNA fragments or recombinant DNA molecules may comprise other nucleic acid sequences such as the immune-stimulating oligonucleotides having unmethylated 10 CpG di-nucleotides, or nucleic acid sequences that code for other antigenic proteins or adjuvating cytokines.
Thus, both in view of their use in expression systems and their use in DNA
vaccination, another embodiment of the invention relates to nucleic acid sequences 15 encoding an 200 kD protein or an immunogenic fragment of that protein comprising a nucleic acid sequence that has a identity of at least 70%, preferably 75%, more preferably 80% or even 85%, 90%, 92%, preferably 94%, more preferably 95%, even more preferred 96%, 97%, 98%, 99% or even 100% in that order of preference identity with the the nucleic acid sequence depicted in SEQ ID NO: 1.
The percentage of identity between any nucleic acid and a nucleic acid according to the invention can be determined with the computer program "BLAST 2 SEQUENCES" by selecting sub-program: "BlastN" (T. Tatusova & T. Madden, 1999, FEMS Microbiol. Letters, vol. 174, p. 247-250), that can be found at the internet address www.ncbi.nlm.nih.gov/blast/bl2seq/b12.htm1. Parameters that are to be used are the default parameters: reward for a match: +l; penalty for a mismatch: -2; open gap penalty: 5; extension gap penalty: 2; and gap x_dropoff: 50.
Unlike the output of the BlastP program described above, the BlastN program does not list similarities, only identities: the percentage of nucleotides that are identical is indicated as "Identities".
Next to using computer algorithms for determining the level of identity/mismatch between any nucleic acid and a nucleic acid according to the invention, experimental techniques can also be used. Especially by hybridisation under conditions of controlled stringency.
The definition of stringent hybridisation conditions, as a function of the identity between two nucleotide sequences, follows from the formula for the melting temperature Tm of Meinkoth and Wahl (1984, Anal. Biochem., vol. 138, p. 267-284):
Tm =[81.5 C + 16.6(log M) + 0.41(%GC) - 0.61(%formamide) - 500/L] - 1 C/1%
mismatch In this formula: M is the molarity of monovalent cations; %GC is the percentage of guanosine and cytosine nucleotides in the DNA; L is the length of the hybrid in base pairs; and "mismatch" is the lack of an identical match.
Washing conditions subsequent to the hybridization can also be made more or less stringent, thereby selecting for higher or lower percentages of identity respectively.
In general, higher stringency is obtained by reducing the salt concentration, and increasing the incubation temperature. It is well within the capacity of the skilled person to select hybridisation conditions that match a certain percentage-level of identity as determined by computer analysis.
Merely as an example, and of course depending upon the G/C content and the length of the fragment: "stringent" washing conditions are conditions of 1 x SSC, 0.1% SDS
at a temperature of 65 C; highly stringent conditions refer to a reduction in SSC
concentration towards 0.3 x SSC.
Another embodiment of the invention relates to nucleic acid sequences encoding an 180 kD protein or an immunogenic fragment of that protein comprising a nucleic acid sequence that has a identity of at least 70%, preferably 75%, more preferably 80% or even 85%, 90%, 92%, preferably 94%, more preferably 95%, even more preferred 96%, 97%, 98%, 99% or even 100% in that order of preference identity with the the nucleic acid sequence depicted in SEQ ID NO: 3.
Another embodiment of the invention relates to nucleic acid sequences encoding an 100/85 kD protein or an immunogenic fragment of that protein comprising a nucleic acid sequence that has a identity of at least 70%, preferably 75%, more preferably 80% or even 85%, 90%, 92%, preferably 94%, more preferably 95%, even more preferred 96%, 97%, 98%, 99% or even 100% in that order of preference identity with the the nucleic acid sequence depicted in SEQ ID NO: 5.
Another embodiment of the invention relates to nucleic acid sequences encoding an 79 kD protein or an immunogenic fragment of that protein comprising a nucleic acid sequence that has a identity of at least 70%, preferably 75%, more preferably 80% or even 85%, 90%, 92%, preferably 94%, more preferably 95%, even more preferred 96%, 97%, 98%, 99% or even 100% in that order of preference identity with the the nucleic acid sequence depicted in SEQ ID NO: 7.
For the purpose of the invention, stringent conditions are those conditions under which a nucleic acid still hybridises if it has a mismatch of 30 %; i.e. if it is 70 %
identical to the (relevant part of the) nucleotide sequence depicted in SEQ ID
NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7.
Therefore, if a nucleic acid hybridises under stringent conditions to the nucleic acid having a nucleotide sequence depicted in SEQ ID NO: 1, SEQ ID NO: 3, SEQ
ID
NO: 5 or SEQ ID NO: 7, it is considered a nucleic acid according to the invention.
In a preferred form of these embodiments, the invention relates to DNA
fragments comprising a nucleic acid sequence encoding the 200 kD protein, the 180 kD
protein, the 100/85 kD protein or the 79 kD protein or an immunogenic part of any of said proteins. A DNA fragment is a stretch of nucleotides that functions as a carrier for a nucleic acid sequence according to the invention. Such DNA fragments can e.g.
be plasmids, into which a nucleic acid sequence according to the invention is cloned.
Such DNA fragments are e.g. useful for enhancing the amount of DNA for use as a primer and for expression of a nucleic acid sequence according to the invention, as described below.
The nucleic acid sequence according to the present invention or the DNA
plasmid comprising a nucleic acid sequence according to the present invention, preferably operably linked to a transcriptional regulatory sequence, to be used in the vaccine according to the invention can be naked or can be packaged in a delivery system.
Suitable delivery systems are lipid vesicles, iscoms, dendromers, niosomes, polysaccharide matrices and the like, (see further below) all well-known in the art.
Also very suitable as delivery system are attenuated live bacteria such as Vibrio species, and attenuated live viruses such as alphavirus vectors, as mentioned above.
A more preferred form of this embodiment of the present invention relates to a recombinant DNA molecule comprising a nucleic acid sequence encoding a 200 kD
protein, the 180 kD protein, the 100/85 kD protein or the 79 kD protein or an immunogenic part of any of said proteins wherein the nucleic acid sequence is placed under the control of a functionally linked promoter. Such recombinants can be obtained by means of e.g. standard molecular biology techniques.
(Maniatis/Sambrook (Sambrook, J. Molecular cloning: a laboratory manual, 1989.
ISBN 0-87969-309-6).
Still other forms of this embodiment relate to recombinant DNA molecules, live recombinant carriers and host cells comprising a nucleic acids sequence as described above for use in a vaccine.
Another embodiment of the present invention relates to vaccines comprising recombinant DNA molecules, live recombinant carriers and host cells comprising a nucleic acids sequence as described above.
Again another embodiment of the present invention relates to the use of a nucleic acid sequence, a DNA fragment, a recombinant DNA molecule, a Live Recombinant Carrier or a host cell as described above, for the manufacturing of a vaccine for combating sea louse infections.
DNA vaccines can easily be administered through intradermal application e.g.
using a needle-less injector. This way of administration delivers the DNA directly into the cells of the animal to be vaccinated. Amounts of DNA in the range between 10 pg and 1000 g provide good results. Preferably, amounts in the microgram range between 1 and 100 g are used. Alternatively, animals can be dipped in solutions comprising e.g.
between 10 pg and 1000 g per ml of the DNA to be administered.
In a further embodiment, the vaccine according to the present invention additionally comprises one or more antigens derived from fish pathogenic organisms such as sea lice, micro-organisms and viruses, antibodies against those antigens or genetic information encoding such antigens.
Of course, such antigens can be e.g. other sea lice antigens. Such an antigen can also be an antigen selected from other fish pathogenic organisms, micro-organisms and viruses. Such organisms and viruses are preferably selected from the group of aquatic birnaviruses such as infectious pancreatic necrosis virus (IPNV), aquatic nodaviruses such as striped jack nervous necrosis virus (SJNNV), aquatic rhabdoviruses such as infectious haematopoietic necrosis virus (IHNV) and viral haemorrhagic septicaemia virus (VHSV), Pancreas Disease virus (SPDV) and aquatic orthomyxoviruses such as infectious salmon anaemia virus and the group of fish pathogenic bacteria such as Flexibacter columnaris, Edwardsialla ictaluri, E. tarda, Yersinia ruckeri, Pasteurella piscicida, Vibrio anguillarum, Aeromonas salmonicida and Renibacterium salmoninarum All vaccines according to the present invention comprise a pharmaceutically acceptable carrier. A pharmaceutically acceptable carrier can be e.g. sterile water or a sterile physiological salt solution. In a more complex form the carrier can e.g. be a buffer.
Methods for the preparation of a vaccine comprise the admixing of the 200 kD
protein, the 180 kD protein, the 100/85 kD protein or the 79 kD protein or an immunogenic part of any of said proteins and/or antibodies against that protein or an immunogenic fragment thereof, and/or a nucleic acid sequence and/or a DNA
fragment, a recombinant DNA molecule, a live recombinant carrier or host cell according to the invention, and a pharmaceutically acceptable carrier.
Vaccines according to the present invention may in a preferred presentation also contain an immunostimulatory substance, a so-called adjuvant. Adjuvants in general comprise substances that boost the immune response of the host in a non-specific manner. A number of different adjuvants are known in the art. Examples of adjuvants frequently used in fish and shellfish farming are muramyldipeptides, lipopolysaccharides, several glucans and glycans and Carbopol(R) (a homopolymer).
5 An extensive overview of adjuvants suitable for fish and shellfish vaccines is given in the review paper by Jan Raa (Reviews in Fisheries Science 4(3): 229-288 (1996)).
The vaccine may also comprise a so-called "vehicle". A vehicle is a compound to which the protein adheres, without being covalently bound to it. Such vehicles are i.a.
bio-microcapsules, micro-alginates, liposomes and macrosols, all known in the art.
10 A special form of such a vehicle, in which the antigen is partially embedded in the vehicle, is the so-called ISCOM (EP 109.942, EP 180.564, EP 242.380) In addition, the vaccine may comprise one or more suitable surface-active compounds or emulsifiers, e.g. Span or Tween.
15 Often, the vaccine is mixed with stabilisers, e.g. to protect degradation-prone proteins from being degraded, to enhance the shelf-life of the vaccine, or to improve freeze-drying efficiency. Useful stabilisers are i.a. SPGA (Bovamik et al; J.
Bacteriology 59:
509 (1950)), carbohydrates e.g. sorbitol, mannitol, trehalose, starch, sucrose, dextran or glucose, proteins such as albumin or casein or degradation products thereof, and 20 buffers, such as alkali metal phosphates. Preferably, the vaccines according to the invention are in a freeze-dried form. Freeze-dried proteins and DNA have a much longer shelf-live, especially at room temperature, than when they are in a liquid form.
The process of freeze-drying as such is extensively known in the art.
In addition, the vaccine may be suspended in a physiologically acceptable diluent.
It goes without saying, that other ways of adjuvating, adding vehicle compounds or diluents, emulsifying or stabilizing a protein are also embodied in the present invention.
Vaccines according to the invention that are based upon the 200 kD protein, the 180 kD protein, the 100/85 kD protein or the 79 kD protein or an immunogenic part of any of said proteins can very suitably be administered in amounts ranging between 1 and 100 micrograms of protein per animal, although smaller doses can in principle be used. A dose exceeding 100 micrograms will, although immunologically very suitable, be less attractive for commercial reasons.
Vaccines based upon live attenuated recombinant carriers, such as the LRC-viruses and bacteria described above can be administered in much lower doses, because they multiply themselves during the infection. Therefore, very suitable amounts would range between 103 and 109 CFU/PFU for bacteria and viruses.
Many ways of administration, all known in the art can be applied. The protein-based vaccines according to the invention are preferably administered to the fish via injection, immersion, dipping or per oral. The administration protocol can be optimized in accordance with standard vaccination practice. Preferably the vaccine is administered via immersion or per oral, especially in case of commercial aqua culture farms.
For oral administration the vaccine is preferably mixed with a suitable carrier for oral administration i.e. cellulose, food or a metabolisable substance such as alpha-cellulose or different oils of vegetable or animals origin. Also an attractive way of administration is administration of the vaccine to high concentrations of live-feed organisms, followed by feeding the live-feed organisms to the target animal, e.g. the fish. Particularly preferred food carriers for oral delivery of the vaccine according to the invention are live-feed organisms which are able to encapsulate the vaccine.
Suitable live-feed organisms include plankton-like non-selective filter feeders preferably members of Rotifera, Artemia, and the like. Highly preferred is the brine shrimp Artemia sp..
A very elegant way of administration would be the following: bacteria, yeast cells or any other cell in which the protein according to the invention has been synthesised are directly fed to plankton-like non-selective filter feeders preferably members of Rotifera, Artemia, and the like. The pharmaceutical composition so made, and comprising i.e. those bacteria, yeast cells or any other cell ingested by plankton-like non-selective filter feeders can then be administered orally to the crustaceans to be protected against viral infection.
Another embodiment of the invention relates to nucleic acid sequences encoding an 79 kD protein or an immunogenic fragment of that protein comprising a nucleic acid sequence that has a identity of at least 70%, preferably 75%, more preferably 80% or even 85%, 90%, 92%, preferably 94%, more preferably 95%, even more preferred 96%, 97%, 98%, 99% or even 100% in that order of preference identity with the the nucleic acid sequence depicted in SEQ ID NO: 7.
For the purpose of the invention, stringent conditions are those conditions under which a nucleic acid still hybridises if it has a mismatch of 30 %; i.e. if it is 70 %
identical to the (relevant part of the) nucleotide sequence depicted in SEQ ID
NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7.
Therefore, if a nucleic acid hybridises under stringent conditions to the nucleic acid having a nucleotide sequence depicted in SEQ ID NO: 1, SEQ ID NO: 3, SEQ
ID
NO: 5 or SEQ ID NO: 7, it is considered a nucleic acid according to the invention.
In a preferred form of these embodiments, the invention relates to DNA
fragments comprising a nucleic acid sequence encoding the 200 kD protein, the 180 kD
protein, the 100/85 kD protein or the 79 kD protein or an immunogenic part of any of said proteins. A DNA fragment is a stretch of nucleotides that functions as a carrier for a nucleic acid sequence according to the invention. Such DNA fragments can e.g.
be plasmids, into which a nucleic acid sequence according to the invention is cloned.
Such DNA fragments are e.g. useful for enhancing the amount of DNA for use as a primer and for expression of a nucleic acid sequence according to the invention, as described below.
The nucleic acid sequence according to the present invention or the DNA
plasmid comprising a nucleic acid sequence according to the present invention, preferably operably linked to a transcriptional regulatory sequence, to be used in the vaccine according to the invention can be naked or can be packaged in a delivery system.
Suitable delivery systems are lipid vesicles, iscoms, dendromers, niosomes, polysaccharide matrices and the like, (see further below) all well-known in the art.
Also very suitable as delivery system are attenuated live bacteria such as Vibrio species, and attenuated live viruses such as alphavirus vectors, as mentioned above.
A more preferred form of this embodiment of the present invention relates to a recombinant DNA molecule comprising a nucleic acid sequence encoding a 200 kD
protein, the 180 kD protein, the 100/85 kD protein or the 79 kD protein or an immunogenic part of any of said proteins wherein the nucleic acid sequence is placed under the control of a functionally linked promoter. Such recombinants can be obtained by means of e.g. standard molecular biology techniques.
(Maniatis/Sambrook (Sambrook, J. Molecular cloning: a laboratory manual, 1989.
ISBN 0-87969-309-6).
Still other forms of this embodiment relate to recombinant DNA molecules, live recombinant carriers and host cells comprising a nucleic acids sequence as described above for use in a vaccine.
Another embodiment of the present invention relates to vaccines comprising recombinant DNA molecules, live recombinant carriers and host cells comprising a nucleic acids sequence as described above.
Again another embodiment of the present invention relates to the use of a nucleic acid sequence, a DNA fragment, a recombinant DNA molecule, a Live Recombinant Carrier or a host cell as described above, for the manufacturing of a vaccine for combating sea louse infections.
DNA vaccines can easily be administered through intradermal application e.g.
using a needle-less injector. This way of administration delivers the DNA directly into the cells of the animal to be vaccinated. Amounts of DNA in the range between 10 pg and 1000 g provide good results. Preferably, amounts in the microgram range between 1 and 100 g are used. Alternatively, animals can be dipped in solutions comprising e.g.
between 10 pg and 1000 g per ml of the DNA to be administered.
In a further embodiment, the vaccine according to the present invention additionally comprises one or more antigens derived from fish pathogenic organisms such as sea lice, micro-organisms and viruses, antibodies against those antigens or genetic information encoding such antigens.
Of course, such antigens can be e.g. other sea lice antigens. Such an antigen can also be an antigen selected from other fish pathogenic organisms, micro-organisms and viruses. Such organisms and viruses are preferably selected from the group of aquatic birnaviruses such as infectious pancreatic necrosis virus (IPNV), aquatic nodaviruses such as striped jack nervous necrosis virus (SJNNV), aquatic rhabdoviruses such as infectious haematopoietic necrosis virus (IHNV) and viral haemorrhagic septicaemia virus (VHSV), Pancreas Disease virus (SPDV) and aquatic orthomyxoviruses such as infectious salmon anaemia virus and the group of fish pathogenic bacteria such as Flexibacter columnaris, Edwardsialla ictaluri, E. tarda, Yersinia ruckeri, Pasteurella piscicida, Vibrio anguillarum, Aeromonas salmonicida and Renibacterium salmoninarum All vaccines according to the present invention comprise a pharmaceutically acceptable carrier. A pharmaceutically acceptable carrier can be e.g. sterile water or a sterile physiological salt solution. In a more complex form the carrier can e.g. be a buffer.
Methods for the preparation of a vaccine comprise the admixing of the 200 kD
protein, the 180 kD protein, the 100/85 kD protein or the 79 kD protein or an immunogenic part of any of said proteins and/or antibodies against that protein or an immunogenic fragment thereof, and/or a nucleic acid sequence and/or a DNA
fragment, a recombinant DNA molecule, a live recombinant carrier or host cell according to the invention, and a pharmaceutically acceptable carrier.
Vaccines according to the present invention may in a preferred presentation also contain an immunostimulatory substance, a so-called adjuvant. Adjuvants in general comprise substances that boost the immune response of the host in a non-specific manner. A number of different adjuvants are known in the art. Examples of adjuvants frequently used in fish and shellfish farming are muramyldipeptides, lipopolysaccharides, several glucans and glycans and Carbopol(R) (a homopolymer).
5 An extensive overview of adjuvants suitable for fish and shellfish vaccines is given in the review paper by Jan Raa (Reviews in Fisheries Science 4(3): 229-288 (1996)).
The vaccine may also comprise a so-called "vehicle". A vehicle is a compound to which the protein adheres, without being covalently bound to it. Such vehicles are i.a.
bio-microcapsules, micro-alginates, liposomes and macrosols, all known in the art.
10 A special form of such a vehicle, in which the antigen is partially embedded in the vehicle, is the so-called ISCOM (EP 109.942, EP 180.564, EP 242.380) In addition, the vaccine may comprise one or more suitable surface-active compounds or emulsifiers, e.g. Span or Tween.
15 Often, the vaccine is mixed with stabilisers, e.g. to protect degradation-prone proteins from being degraded, to enhance the shelf-life of the vaccine, or to improve freeze-drying efficiency. Useful stabilisers are i.a. SPGA (Bovamik et al; J.
Bacteriology 59:
509 (1950)), carbohydrates e.g. sorbitol, mannitol, trehalose, starch, sucrose, dextran or glucose, proteins such as albumin or casein or degradation products thereof, and 20 buffers, such as alkali metal phosphates. Preferably, the vaccines according to the invention are in a freeze-dried form. Freeze-dried proteins and DNA have a much longer shelf-live, especially at room temperature, than when they are in a liquid form.
The process of freeze-drying as such is extensively known in the art.
In addition, the vaccine may be suspended in a physiologically acceptable diluent.
It goes without saying, that other ways of adjuvating, adding vehicle compounds or diluents, emulsifying or stabilizing a protein are also embodied in the present invention.
Vaccines according to the invention that are based upon the 200 kD protein, the 180 kD protein, the 100/85 kD protein or the 79 kD protein or an immunogenic part of any of said proteins can very suitably be administered in amounts ranging between 1 and 100 micrograms of protein per animal, although smaller doses can in principle be used. A dose exceeding 100 micrograms will, although immunologically very suitable, be less attractive for commercial reasons.
Vaccines based upon live attenuated recombinant carriers, such as the LRC-viruses and bacteria described above can be administered in much lower doses, because they multiply themselves during the infection. Therefore, very suitable amounts would range between 103 and 109 CFU/PFU for bacteria and viruses.
Many ways of administration, all known in the art can be applied. The protein-based vaccines according to the invention are preferably administered to the fish via injection, immersion, dipping or per oral. The administration protocol can be optimized in accordance with standard vaccination practice. Preferably the vaccine is administered via immersion or per oral, especially in case of commercial aqua culture farms.
For oral administration the vaccine is preferably mixed with a suitable carrier for oral administration i.e. cellulose, food or a metabolisable substance such as alpha-cellulose or different oils of vegetable or animals origin. Also an attractive way of administration is administration of the vaccine to high concentrations of live-feed organisms, followed by feeding the live-feed organisms to the target animal, e.g. the fish. Particularly preferred food carriers for oral delivery of the vaccine according to the invention are live-feed organisms which are able to encapsulate the vaccine.
Suitable live-feed organisms include plankton-like non-selective filter feeders preferably members of Rotifera, Artemia, and the like. Highly preferred is the brine shrimp Artemia sp..
A very elegant way of administration would be the following: bacteria, yeast cells or any other cell in which the protein according to the invention has been synthesised are directly fed to plankton-like non-selective filter feeders preferably members of Rotifera, Artemia, and the like. The pharmaceutical composition so made, and comprising i.e. those bacteria, yeast cells or any other cell ingested by plankton-like non-selective filter feeders can then be administered orally to the crustaceans to be protected against viral infection.
The following examples are illustrative for the invention and should not be interpreted as limitations of the invention.
EXAMPLES
Example 1:
1. Vaccination and challenge Vaccine preparation Salmon lice eggs were hatched in incubators with flowing seawater (34,5%o , 20uM
filtered). After development to the infectious copepodid stage, lice were added to tanks containing Atlantic salmon (S. salar) and left natural development.
Adult egg producing L. salmonis (Ls) females were collected with forceps from anaesthetized fish and oocytes harvested by puncturing the gonade section. Water-soluble proteins were extracted by resuspending oocytes from 501ice in 2.5 ml of cold sonication buffer (50 mM Tris-HC1 pH 7.5, 50mM NaC1 and 1mM EDTA) and eggs were disrupted by sonication using a micro ultrasonic cell disrupter. The sonicated extract was clarified by centrifugation (13000g for 20 min at 4 C), pellet and lipids discarded and the supematant stored at -20 C.
The supematant total protein content was analyzed by SDS-PAGE and Coomassie staining and quantified relative to known quantities of BSA.
The Ls protein extract were diluted to app. 5mg/ml (BSA equivalents) with ddHzO and added 0,1% (voUvol) of 37% formaldehyde. A 5mg/ml BSA control antigen was prepared simultaneously. Vaccines were prepared by emulsification of 27% (w/w) of antigen in 67% ISA763 oil (Seppic).
Vaccination and challenge experiment 50 Atlantic salmon pre-smolt (app 40g) were vaccinated by individually intraperitonal injection of 150u1 vaccine (approximately 200ug protein). A control group (n=50) was vaccinated with the control vaccine containing BSA (200ug/dose). All fish were kept at 10 C in one circular 1200 L tank. Clipping of the adipose fin differentiated the two groups. Fish were kept on natural light and were adapted to salt water during week 9-11 post vaccination. The groups were challenged (15 weeks post vaccination) as one population, by adding approximately 2,600 infective copepodids to the tank, following reduction in water volume and flow. The fish were maintained in the thank for two weeks for parasite development into the immobile physically attached Chalimus stage, and then transferred to three different 250 L tanks; Tank 1 and 2 contained control and vaccinated fish, respectively (n=25) and tank 3 contained a mixed group of vaccinated and control vaccinated fish (n=25+25).
The experiment was terminated 11 weeks post challenge, three weeks after the first egg string was observed on adult female lice. Vaccine effect was evaluated by comparing prevalence (percentage of fish infected) and the abundance (number of lice/fish). Furthermore, fish-pathology (external wounds) was compared between tank 1(control) and tank 2 (vaccine) only. All fish were anaesthetized before handling and sampling of animals were conducted in accordance with national legislation.
2. Identification of genes encoding proteins in the vaccine The protein content of the vaccine antigen was analyzed by SDS-PAGE, using 10-20% Linear Gradient Ready Gel (BioRad) and commercially prepared running buffer and Coomassie stain. Protein band A was excised from the gel and internal amino acid sequence analysis was performed by EuroSequence bv, essentially as described by Rosenfeld et al. (Annal. Biochem. 203:173-179 (1992)). This includes in-situ tryptic digestion of the protein band, extraction of the peptides and RP-HPLC
separation of the generated fragments. On purified fragments, identification of the step-wise released PTH-amino acid (Hewick et al., J. Biol. Chem. 256: 7990-7997 (1981)) fragments was determined using an Applied Biosystems Mode1494 Procise Sequencing system, on-line connected to an RP-HPLC unit.
The internal peptide sequences were back-translated and used to search an internal database of salmon louse ESTs for gene transcripts encoding the peptide sequences.
Following this, overlapping ESTs clones were identified and, supplemented by RACE
clones, full-length cDNA sequences were assembled using Vector NTI 9.1.0 (Invitrogen). Blast searches were performed to identify protein domains and to indicate gene function.
EXAMPLES
Example 1:
1. Vaccination and challenge Vaccine preparation Salmon lice eggs were hatched in incubators with flowing seawater (34,5%o , 20uM
filtered). After development to the infectious copepodid stage, lice were added to tanks containing Atlantic salmon (S. salar) and left natural development.
Adult egg producing L. salmonis (Ls) females were collected with forceps from anaesthetized fish and oocytes harvested by puncturing the gonade section. Water-soluble proteins were extracted by resuspending oocytes from 501ice in 2.5 ml of cold sonication buffer (50 mM Tris-HC1 pH 7.5, 50mM NaC1 and 1mM EDTA) and eggs were disrupted by sonication using a micro ultrasonic cell disrupter. The sonicated extract was clarified by centrifugation (13000g for 20 min at 4 C), pellet and lipids discarded and the supematant stored at -20 C.
The supematant total protein content was analyzed by SDS-PAGE and Coomassie staining and quantified relative to known quantities of BSA.
The Ls protein extract were diluted to app. 5mg/ml (BSA equivalents) with ddHzO and added 0,1% (voUvol) of 37% formaldehyde. A 5mg/ml BSA control antigen was prepared simultaneously. Vaccines were prepared by emulsification of 27% (w/w) of antigen in 67% ISA763 oil (Seppic).
Vaccination and challenge experiment 50 Atlantic salmon pre-smolt (app 40g) were vaccinated by individually intraperitonal injection of 150u1 vaccine (approximately 200ug protein). A control group (n=50) was vaccinated with the control vaccine containing BSA (200ug/dose). All fish were kept at 10 C in one circular 1200 L tank. Clipping of the adipose fin differentiated the two groups. Fish were kept on natural light and were adapted to salt water during week 9-11 post vaccination. The groups were challenged (15 weeks post vaccination) as one population, by adding approximately 2,600 infective copepodids to the tank, following reduction in water volume and flow. The fish were maintained in the thank for two weeks for parasite development into the immobile physically attached Chalimus stage, and then transferred to three different 250 L tanks; Tank 1 and 2 contained control and vaccinated fish, respectively (n=25) and tank 3 contained a mixed group of vaccinated and control vaccinated fish (n=25+25).
The experiment was terminated 11 weeks post challenge, three weeks after the first egg string was observed on adult female lice. Vaccine effect was evaluated by comparing prevalence (percentage of fish infected) and the abundance (number of lice/fish). Furthermore, fish-pathology (external wounds) was compared between tank 1(control) and tank 2 (vaccine) only. All fish were anaesthetized before handling and sampling of animals were conducted in accordance with national legislation.
2. Identification of genes encoding proteins in the vaccine The protein content of the vaccine antigen was analyzed by SDS-PAGE, using 10-20% Linear Gradient Ready Gel (BioRad) and commercially prepared running buffer and Coomassie stain. Protein band A was excised from the gel and internal amino acid sequence analysis was performed by EuroSequence bv, essentially as described by Rosenfeld et al. (Annal. Biochem. 203:173-179 (1992)). This includes in-situ tryptic digestion of the protein band, extraction of the peptides and RP-HPLC
separation of the generated fragments. On purified fragments, identification of the step-wise released PTH-amino acid (Hewick et al., J. Biol. Chem. 256: 7990-7997 (1981)) fragments was determined using an Applied Biosystems Mode1494 Procise Sequencing system, on-line connected to an RP-HPLC unit.
The internal peptide sequences were back-translated and used to search an internal database of salmon louse ESTs for gene transcripts encoding the peptide sequences.
Following this, overlapping ESTs clones were identified and, supplemented by RACE
clones, full-length cDNA sequences were assembled using Vector NTI 9.1.0 (Invitrogen). Blast searches were performed to identify protein domains and to indicate gene function.
3. Evaluation of protein antigenicity Immunization of rabbits with purified protein The 200 kD protein, the 180 kD protein, the 100 and 85 kD proteins and the 79 kD
protein were purified by preparative SDS-PAGE using a Prep Cell mode1491 (BioRad) according to the manufacturer instructions. Purified protein was analysed by SDS-PAGE and Coomassie staining, and quantified relative to BSA as described above. One rabbit was immunized with the purified 200 kD protein, one with the purified 180 kD protein, one with the purified 100 D protein, one with the purified 85 kD protein and one with the purified 79 kD protein by Eurogentec at their facility using their immunisation protocol (boost at day 14, 28 and 56).
Immunisation of Atlantic salmon with all vaccine antigens Vaccine antigen from L. salmonis was prepared as described above (5mg/ml) mixed 1:1 with Freud's complete adjuvant and vortexed until homogeneity. 5 Atlantic salmon (app 250g) were immunised by intraperitoneal injection of 150u1 (app.
375ug protein). Blood were collected 9 weeks post immunisation and left at 4 C
overnight for coagulation. Antisera were aliquoted and stored at -20 C until used.
Rabbit antisera analysis Rabbit anti-200 kD protein antiserum, anti-180 kD protein antiserum, anti-100 kD
protein antiserum, anti-85 kD protein antiserum and anti-79 kD protein antiserum were analysed by Western blotting (using a blot comprising all egg proteins) and by ELISA using single purified proteins as antigen.
Briefly, Western blotting was performed by SDS-PAGE as described above followed by blotting onto nitrocellulose (150V for 45 min using 25mM Tris, 192mM
glycin, 20% methanol and cooling) and blocked for 1 hour at room temperature using 3%
non-fat dry milk (Nestle) in TBS-Tween. Nitrocellulose was incubated with rabbit antiserum and pre-serum control (1:1000) for 2 hours at room temperature followed by 3 washes with TBS-Tween. Secondary, nitrocellulose was incubated with horseradish peroxidase conjugated goat anti rabbit antibody (1:2000, BioRad) at room temperature for 1 hour. Following 3 washes with TBS-Tween and 1 with TBS, colorimetric detection was performed using premixed HRP-4CN substrates according to the manufacturer (BioRad).
Briefly, ELISA was performed by coating Nunc immunosorbent plate wells with 100u1 of the 200 kD protein, the 180 kD protein, the 100 kD protein, the 85 kD
protein or the 79 kD protein purified from eggs (using the egg 35 kD protein as control) diluted to app 2ug/ml in coating buffer (15mM NazCO3, 35mM NaHCO3, pH
5 9.6), and incubate at 4 C over night. Wells were then washed twice with PBS-Tween, blocked with 5% non-fat dry milk (Nestle) in PBS-Tween (200u1/well) for 1 hour at room temperature and washed again. Twofold dilutions of rabbit antiserum (from 1:2000) were incubated (100uUwell) for 2 hours at room temperature followed by washes with PBS-Tween. Secondary, horseradish peroxidase conjugated goat-anti-10 rabbit antibody (1:3000, BioRad) were added (100uUwe11) and incubated at room temperature for 1 hour. Following 4 washes with PBS-Tween and 1 with PBS, colour was developed for 20 minutes using 150u1 o-phenylenediamine dihydrocloride (0,4 mg/ml in phosphate-citrate buffer pH 5 added fresh H202 to 0,012%) to each well.
Reaction was stopped by adding 50u12,5N H2SO4 before absorbance was measured at 15 492nm.
Salmon antisera analysis Antisera from 5 Atlantic salmons immunised with the vaccine antigens were analysed by ELISA using either purified egg 200 kD protein, 180 kD protein, 100 kD
protein, 20 85 kD protein or 79 kD protein as antigen. Briefly, this was performed as described for rabbit antisera analysis but diluting the antisera from 1:25 and incubating at 4 C
over night. Furthermore, an incubation step with rabbit anti-salmon-Ig 0206 (1:6000, 1 hour at room temperature) was added between the salmon antisera and the horseradish peroxidase conjugated goat-anti-rabbit antibody.
4. Identification of homolog antigen in other copepod ectoparasites.
Comparison of homolog antigen in other copepod ectoparasites The protein content of external egg strings of L. salmonis (lab strain), Caligus curtus (4th generation lab strain kept on cod) and Caligus rogercresseyi (collected from salmon on-growing farm in Chile) was compared. Water-soluble egg proteins were extracted from the egg strings (15u1 buffer/cm egg string) using sonication as described for vaccine preparation. The supernatant total protein content was analyzed as described above using SDS-PAGE followed by Coomassie staining and by Western blotting as described above, using the rabbit anti L. salmonis egg 200 kD
protein, 180 kD protein, 100 kD protein, 85 kD protein or 79 kD protein antiserum.
Results 1. Vaccine experiment No differences in fish weight, length and condition factor were observed between the experimental groups (tanks 1-3), demonstrating equal conditions between the tanks.
Both prevalence and abundance of adult female lice was lower in tank 2 (vaccine) compared to the tank 1(control). Prevalence and abundance of male lice did not differ significantly between the two tanks, indicating an increased mortality of female lice in the vaccinated group (Fig 1). Furthermore, 80% of the vaccinated fish (tank 2) had no pathology, while 80% of the control fish (tank 1) had erosion or wounds (Fig 2).
In tank 3 (mixed groups), prevalence and abundance did not vary significantly between vaccinated and control fish (Fig 1). However, on both vaccinated and control fish a skew sex ratio was observed, with increased number of males for each female, unlike the typical l:l ratio as seen in tank 1(Table 1). A skew sex ratio of lice has never been observed in the lab before independent of density of fish. A skew sex ratio was also observed in tank 2 were abundance and prevalence demonstrate vaccine effect. This indicates that lice in tank 3 have jumped between hosts and therefore all lice in tank 3 may have fed partly on vaccinated fish.
Table 1. Total number of salmon lice and sex ratio in experimental groups of vaccinated Atlantic salmon Separate tanks (tank 1 and 2) Mixed tank (tank 3) Control Vaccine Control Vaccine Male 72 48 40 41 Female 71 16 16 10 Ratio male/female 1,0 2,7 2,5 4,1 2. Identification of genes encoding proteins in the vaccine preparation SDS-PAGE of unfertilized eggs from L. salmonis revealed 5 major bands with approximate molecular weight of 200 kD, 160 kD, 100 kD, 85 kD and 35K kD, called egg-band A-E respectively (Fig 3).
Three peptide sequences were obtained for egg protein A, the 200 kD protein according to the invention (Table 2) and EST's encoding the peptide sequences were identified in an in-house salmon louse EST database. The full-length cDNA
sequence was successfully assembled based on overlapping ESTs and RACE clones. An in silico analysis of the egg-band A encoding cDNA sequence V6x (SEQ ID NO: 1), revealed that it is a protein that possesses key features of a Vitelogenin (Table 2).
Band A in the oocyte is approximately 200 kD, which correlates well with the ORF and with Northern blot transcript analysis (data not shown).
Table 2. The peptide sequences obtained from isolated egg-band A and the identified gene that encodes egg-band A. Indications of protein-domains are also given.
Table 2.
Mw Internal peptide Identified cDNA / aa Signal Protein domain isolated sequences Gene length peptide protein 200 kD 1. YSPSYYGXAPXL V6x* 6,093* / Yes LPD-N + VWD
2. KDETLLEAFVSR 1,965 3. TXGNLFMEYPE
* See SEQ ID NO: 1 for cDNA sequence Three peptide sequences were obtained for egg protein B, the 180 kD protein according to the invention (Table 3) and EST's encoding the peptide sequences were identified in an in-house salmon louse EST database. The full-length cDNA
sequence was successfully assembled based on overlapping ESTs and RACE clones. An in silico analysis of the egg-band B encoding cDNA sequence Vlx (SEQ ID NO: 3), revealed that it is a protein that possesses key features of a Vitelogenin.
Band B in the oocyte is approximately 180 kD, which correlates well with the V6X ORF and with Northern blot transcript analysis (data not shown).
Table 3. The peptide sequences obtained from isolated egg-band B and the identified gene that encodes egg-band B. Indications of protein-domains are also given.
Mw Internal peptide Identified cDNA / aa Signal Protein domain isolated sequences Gene length peptide protein 180 kD 1 GYGGEYSYXVIGS Vlx* 4,747* / Yes LPD-N + VWD
2 EGYLATGQFFEXD 1,521 Table 3.
* See SEQ ID NO: 3 for cDNA sequence One peptide sequence was obtained for egg protein C and one peptide sequence was obtained for egg protein D (Table 4) and EST's encoding the peptide sequences were identified in an in-house salmon louse EST database. A full-length cDNA
sequence was successfully assembled based on overlapping ESTs and RACE clones and revealed that egg protein C and D are encoded by the same gene. According to in silco analysis this gene sequence encodes a protein that possesses key features of a Vitelogenin. The molecular weight of the egg proteins and C and D together is approximately 185 Kda, which correlates well with the open reading frame of the gene and with Northern blot transcript analysis. However, in the L. salmonis oocyte the protein encoded by this gene is apparently processed into one N-terminal part (band D) and one C-terminal part (band C).
Mw Internal peptide Identified cDNA / aa Signal Protein domain isolated sequences Gene length peptide protein 100 kD QGGSTLXSXMPY C%* 5,948* / Yes LPD-N + VWD
85 kD LLSGIPGLRPHFSGIG 1,903 Table 4.
* See SEQ ID NO: 5 for cDNA sequence One peptide sequences was obtained for egg protein E (Table 5) and EST
encoding the peptide sequence was identified in an in-house salmon louse EST database.
The full-length cDNA sequence was successfully assembled based on overlapping ESTs and RACE clones. According to in silco analysis the eggband E cDNA sequence (SEQ ID NO: 7) encodes a protein of unknown function with molecular weight of KDa. This correlates well with Northern blot transcript analysis (data not shown), indicating that egg-band E (79 kDa) has been processed. The ORF encoded protein has a signal peptide and 3 fasciclin (FAS 1) domains, an extracellular domain suggested to represent an ancient cell adhesion domain common to plants and animals.
Table 5. The peptide sequences obtained from isolated egg-band E and the identified gene that encodes egg-band E. Indications of protein-domains are also given.
Mw Internal peptide Identified cDNA / aa Signal Protein domain isolated sequences Gene length peptide protein 79 kD GTWFTPGLISGQSVK Band E* 2,511* / Yes FAS1 x3 Table 5.
* See SEQ ID NO: 7 for cDNA sequence 3. Evaluation of protein antigenicity Each of the purified egg protein A, B, C, D and E (Fig 4-7) used for the immunization of rabbits induced high levels of specific antibodies, as can be seen from figure 8-11.
These antibodies bind only and specifically to either the 200 kD protein, the 180 kD
protein, the 100 kD protein, the 85 kD protein or the 79 kD protein on a Western blot of gels comprising all proteins as antigen (Fig 12-15).
The vaccine antigens (all egg proteins A-E) induced, when used together for the immunization of Atlantic salmon, production of antibodies against the purified kD protein, the 180 kD protein, the 100 kD protein, the 85 kD protein or the 79 kD
protein egg-band, as can be clearly seen from figure 16-19.
Conclusion: it follows from the experiments above that each of the proteins according to the invention; the 200 kD protein, the 180 kD protein, the 100 kD protein, the 85 kD protein or the 79 kD protein of the egg protein preparation are capable of inducing protection against sea lice, are highly immunogenic and are recognized by both antibodies raised against them in rabbits and antibodies raised in fish 5 4. Identification of homolog antigens in other copepod ectoparasites SDS-PAGE and Coomassie total protein staining of egg-proteins from L.
salmonis, Caligus curtus and Caligus rogercresseyi showed that all three species have a similar egg protein pattern (Fig 20a-23a). Western blotting of the same egg proteins demonstrated that each of the rabbit anti L. salmonis egg-bands A, B, C, D and E, 10 corresponding to the 200 kD, 180 kD, 100 kD, 85 kD and 79 kD proteins specifically bind to a homolog protein in both Caligus species (Fig 20b, 21b, 22b, 22c, 23b).
Conclusion: it can be concluded that protection on the basis of the 200 kD, 180 kD, 100 kD, 85 kD and 79 kD protein according to the invention is not only feasible against L. salmonis, but equally well against Caligus spp.
Legend to the figures Figure 1. Prevalence (A) and abundance (B) of adult salmon lice on vaccinated Atlantic salmon smolt 11 weeks post challenge (26 weeks post vaccination).
Figure 2. Frequency and level of salmon lice induced external pathology on vaccinated (tank 2) and control vaccinated (tank 1) Atlantic salmon, 11 weeks post challenge with salmon louse.
Figure 3. SDS-PAGE and Coomassie brilliant blue (total protein stain) analysis of vaccine antigen preparation.
Figure 4. SDS-PAGE and Coomassie brilliant blue (total protein stain) analysis of purified egg-band A (lane 2) and crude vaccine antigen preparation (lane 3).
Molecular weight standard is to the left (lane 1).
Figure 5. SDS-PAGE and Coomassie brilliant blue (total protein stain) analysis of purified egg-band B (lane 2) and crude vaccine antigen preparation (lane 3).
Molecular weight standard is to the left (lane 1).
Figure 6. SDS-PAGE and Coomassie brilliant blue (total protein stain) analysis of purified egg band C (lane 2), D (lane 5) and crude vaccine antigen preparation (duplicated in lanes 3 and 6). Molecular weight standards are in lanes 1 and 4.
Figure 7. SDS-PAGE and Coomassie brilliant blue (total protein stain) analysis of purified egg-band E (lane 1) and crude vaccine antigen preparation (lane 3).
Molecular weight standard is in lane 2.
Figure 8. Level of antibodies against egg-band A protein, in antisera from rabbits immunised with egg-band A or egg-band E (control serum), analysed by ELISA.
ELISA plates were coated with purified egg-band A protein.
Figure 9. Level of antibodies against egg-band B protein, in antisera from rabbits immunised with eggband B or egg-band E (controlserum), analysed by ELISA.
ELISA plates were coated with purified egg-band B protein.
Figure 10. Level of antibodies aginst egg proteins C and D (figure A and B, respectively), in antisera from rabbits immunised with egg band C, D or egg band E
(controlserum). Sera were analysed by ELISA with plates coated with purified eggband C or D (figure A and B, respectively).
Figure 11. Level of antibodies against egg-band E protein, in antisera from rabbits immunised with egg-band E or egg-band D (control serum), analysed by ELISA.
ELISA plates were coated with purified egg-band E protein.
Figure 12. Antigen-specificity of rabbit anti egg-band A antiserum (A2) analyzed by Western blotting using all vaccine proteins as antigen. A3 was incubated with pre-serum. The vaccine antigen used in the Western blotting (egg-band A-E) is shown in lane B2, a total protein stain of the SDS-PAGE. Identical molecular weight standards are shown in lane Al and Bl.
Figure 13. Antigen-specificity of rabbit anti egg-band B antiserum (A2) analyzed by Western blotting using all vaccine proteins as antigen. A3 was incubated with pre-serum. The vaccine antigen used in the Western blotting (egg-band A-E) is shown in lane B2, a total protein stain of the SDS-PAGE. Identical molecular weight standards are shown in lane Al and Bl.
Figure 14. Antigen-specificity of rabbit anti egg band C and anti egg band D
antiserum (A2 and A3 respectively) analyzed by Western blotting using all vaccine proteins as antigen. A4 was incubated with pre-serum. The vaccine antigen used in the Western blotting (egg band A-E) is shown in lane B2, a total protein stain of the SDS-PAGE. Identical molecular weight standards are shown in lane Al and Bl.
Figure 15. Antigen-specificity of rabbit anti egg-band E antiserum (A2) analyzed by Western blotting using all vaccine proteins as antigen. A3 was incubated with pre-serum. The vaccine antigen used in the Western blotting (egg-band A-E) is shown in lane B2, a total protein stain of the SDS-PAGE. Identical molecular weight standards are shown in lane Al and Bl.
Figure 16. Level of antibodies against egg-band A protein, in antisera from 5 Atlantic salmon immunised with the vaccine antigens. ELISA plates were coated with purified egg-band A protein. Control sera are from un-immunised salmon.
Figure 17. Level of antibodies against egg-band B protein, in antisera from 5 Atlantic salmon immunised with the vaccine antigens. ELISA plates were coated with purified egg-band B protein. Control sera are from un-immunised salmon.
Figure 18. Level of antibodies against egg band C protein (a) and egg band D
protein (b), in antisera from 5 Atlantic salmon immunised with the vaccine antigens.
ELISA
plates were coated with purified egg band C protein (a) and purified egg band D
protein (b). Control sera are from un-immunised salmon.
Figure 19. Level of antibodies against egg-band E protein, in antisera from 5 Atlantic salmon immunised with the vaccine antigens. ELISA plates were coated with purified egg-band E protein. Control sera are from un-immunised salmon.
Figure 20. Analysis of egg protein A in Caligus curtus (C. c) and Caligus rogercresseyi (C. r) compared to Lepeophtheirus salmonis (L. s).
(a) SDS-PAGE and Coomassie staining was performed for total protein analysis of all egg proteins. (b) Western blotting was performed using rabbit anti L. s egg protein A
to analyze for cross binding to homologue gene products in Caligus. (c) Rabbit pre-serum was used as negative Western blotting control. Lanes labeled Std contain identical molecular weight standards.
Figure 21. Analysis of egg proteins (A-E) in Caligus curtus (C. c) and Caligus rogercresseyi (C. r) compared to Lepeophtheirus salmonis (L. s).
(a) SDS-PAGE and Coomassie staining was performed for total protein analysis of all egg proteins. (b) Western blotting was performed using rabbit anti L. s egg protein B
to analyze for cross binding to homologue gene products in Caligus. (c) Rabbit pre-. a J
serum was used as negative Western blotting control. Lanes labeled Std contain identical molecular weight standards.
Figure 22. Analysis of egg proteins C and D in Caligus curtus (C. c) and Caligus rogercresseyi (C. r), compared to Lepeophtheirus salmonis (L. s).
(a) SDS-PAGE and Coomassie staining was performed for total protein analysis of all egg proteins. Western blotting was performed using rabbit anti L. s egg protein C (b) and D (c) to analyze for cross binding to homologue gene products in Caligus.
(d) Rabbit pre-serum was used as negative Western blotting control. Lanes labeled Std contain identical molecular weight standards.
Figure 23. Analysis of egg protein E in Caligus curtus (C. c) and Caligus rogercresseyi (C. r) compared to Lepeophtheirus salmonis (L. s).
(a) SDS-PAGE and Coomassie staining was performed for total protein analysis of all egg proteins. (b) Western blotting was performed using rabbit anti L. s egg protein E
to analyze for cross binding to homologue gene products in Caligus. (c) Rabbit pre-serum was used as negative Western blotting control. Lanes labeled Std contain identical molecular weight standards.
SEQUENCE LISTING IN ELECTRONIC FORM
In accordance with Section 111(1) of the Patent Rules, this description contains a sequence listing in electronic form in ASCII text format (file:
30339-128 Seq 20-MAR-08 vl.txt).
A copy of the sequence listing in electronic form is available from the Canadian Intellectual Property Office.
DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.
NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.
NOTE: For additional volumes please contact the Canadian Patent Office.
protein were purified by preparative SDS-PAGE using a Prep Cell mode1491 (BioRad) according to the manufacturer instructions. Purified protein was analysed by SDS-PAGE and Coomassie staining, and quantified relative to BSA as described above. One rabbit was immunized with the purified 200 kD protein, one with the purified 180 kD protein, one with the purified 100 D protein, one with the purified 85 kD protein and one with the purified 79 kD protein by Eurogentec at their facility using their immunisation protocol (boost at day 14, 28 and 56).
Immunisation of Atlantic salmon with all vaccine antigens Vaccine antigen from L. salmonis was prepared as described above (5mg/ml) mixed 1:1 with Freud's complete adjuvant and vortexed until homogeneity. 5 Atlantic salmon (app 250g) were immunised by intraperitoneal injection of 150u1 (app.
375ug protein). Blood were collected 9 weeks post immunisation and left at 4 C
overnight for coagulation. Antisera were aliquoted and stored at -20 C until used.
Rabbit antisera analysis Rabbit anti-200 kD protein antiserum, anti-180 kD protein antiserum, anti-100 kD
protein antiserum, anti-85 kD protein antiserum and anti-79 kD protein antiserum were analysed by Western blotting (using a blot comprising all egg proteins) and by ELISA using single purified proteins as antigen.
Briefly, Western blotting was performed by SDS-PAGE as described above followed by blotting onto nitrocellulose (150V for 45 min using 25mM Tris, 192mM
glycin, 20% methanol and cooling) and blocked for 1 hour at room temperature using 3%
non-fat dry milk (Nestle) in TBS-Tween. Nitrocellulose was incubated with rabbit antiserum and pre-serum control (1:1000) for 2 hours at room temperature followed by 3 washes with TBS-Tween. Secondary, nitrocellulose was incubated with horseradish peroxidase conjugated goat anti rabbit antibody (1:2000, BioRad) at room temperature for 1 hour. Following 3 washes with TBS-Tween and 1 with TBS, colorimetric detection was performed using premixed HRP-4CN substrates according to the manufacturer (BioRad).
Briefly, ELISA was performed by coating Nunc immunosorbent plate wells with 100u1 of the 200 kD protein, the 180 kD protein, the 100 kD protein, the 85 kD
protein or the 79 kD protein purified from eggs (using the egg 35 kD protein as control) diluted to app 2ug/ml in coating buffer (15mM NazCO3, 35mM NaHCO3, pH
5 9.6), and incubate at 4 C over night. Wells were then washed twice with PBS-Tween, blocked with 5% non-fat dry milk (Nestle) in PBS-Tween (200u1/well) for 1 hour at room temperature and washed again. Twofold dilutions of rabbit antiserum (from 1:2000) were incubated (100uUwell) for 2 hours at room temperature followed by washes with PBS-Tween. Secondary, horseradish peroxidase conjugated goat-anti-10 rabbit antibody (1:3000, BioRad) were added (100uUwe11) and incubated at room temperature for 1 hour. Following 4 washes with PBS-Tween and 1 with PBS, colour was developed for 20 minutes using 150u1 o-phenylenediamine dihydrocloride (0,4 mg/ml in phosphate-citrate buffer pH 5 added fresh H202 to 0,012%) to each well.
Reaction was stopped by adding 50u12,5N H2SO4 before absorbance was measured at 15 492nm.
Salmon antisera analysis Antisera from 5 Atlantic salmons immunised with the vaccine antigens were analysed by ELISA using either purified egg 200 kD protein, 180 kD protein, 100 kD
protein, 20 85 kD protein or 79 kD protein as antigen. Briefly, this was performed as described for rabbit antisera analysis but diluting the antisera from 1:25 and incubating at 4 C
over night. Furthermore, an incubation step with rabbit anti-salmon-Ig 0206 (1:6000, 1 hour at room temperature) was added between the salmon antisera and the horseradish peroxidase conjugated goat-anti-rabbit antibody.
4. Identification of homolog antigen in other copepod ectoparasites.
Comparison of homolog antigen in other copepod ectoparasites The protein content of external egg strings of L. salmonis (lab strain), Caligus curtus (4th generation lab strain kept on cod) and Caligus rogercresseyi (collected from salmon on-growing farm in Chile) was compared. Water-soluble egg proteins were extracted from the egg strings (15u1 buffer/cm egg string) using sonication as described for vaccine preparation. The supernatant total protein content was analyzed as described above using SDS-PAGE followed by Coomassie staining and by Western blotting as described above, using the rabbit anti L. salmonis egg 200 kD
protein, 180 kD protein, 100 kD protein, 85 kD protein or 79 kD protein antiserum.
Results 1. Vaccine experiment No differences in fish weight, length and condition factor were observed between the experimental groups (tanks 1-3), demonstrating equal conditions between the tanks.
Both prevalence and abundance of adult female lice was lower in tank 2 (vaccine) compared to the tank 1(control). Prevalence and abundance of male lice did not differ significantly between the two tanks, indicating an increased mortality of female lice in the vaccinated group (Fig 1). Furthermore, 80% of the vaccinated fish (tank 2) had no pathology, while 80% of the control fish (tank 1) had erosion or wounds (Fig 2).
In tank 3 (mixed groups), prevalence and abundance did not vary significantly between vaccinated and control fish (Fig 1). However, on both vaccinated and control fish a skew sex ratio was observed, with increased number of males for each female, unlike the typical l:l ratio as seen in tank 1(Table 1). A skew sex ratio of lice has never been observed in the lab before independent of density of fish. A skew sex ratio was also observed in tank 2 were abundance and prevalence demonstrate vaccine effect. This indicates that lice in tank 3 have jumped between hosts and therefore all lice in tank 3 may have fed partly on vaccinated fish.
Table 1. Total number of salmon lice and sex ratio in experimental groups of vaccinated Atlantic salmon Separate tanks (tank 1 and 2) Mixed tank (tank 3) Control Vaccine Control Vaccine Male 72 48 40 41 Female 71 16 16 10 Ratio male/female 1,0 2,7 2,5 4,1 2. Identification of genes encoding proteins in the vaccine preparation SDS-PAGE of unfertilized eggs from L. salmonis revealed 5 major bands with approximate molecular weight of 200 kD, 160 kD, 100 kD, 85 kD and 35K kD, called egg-band A-E respectively (Fig 3).
Three peptide sequences were obtained for egg protein A, the 200 kD protein according to the invention (Table 2) and EST's encoding the peptide sequences were identified in an in-house salmon louse EST database. The full-length cDNA
sequence was successfully assembled based on overlapping ESTs and RACE clones. An in silico analysis of the egg-band A encoding cDNA sequence V6x (SEQ ID NO: 1), revealed that it is a protein that possesses key features of a Vitelogenin (Table 2).
Band A in the oocyte is approximately 200 kD, which correlates well with the ORF and with Northern blot transcript analysis (data not shown).
Table 2. The peptide sequences obtained from isolated egg-band A and the identified gene that encodes egg-band A. Indications of protein-domains are also given.
Table 2.
Mw Internal peptide Identified cDNA / aa Signal Protein domain isolated sequences Gene length peptide protein 200 kD 1. YSPSYYGXAPXL V6x* 6,093* / Yes LPD-N + VWD
2. KDETLLEAFVSR 1,965 3. TXGNLFMEYPE
* See SEQ ID NO: 1 for cDNA sequence Three peptide sequences were obtained for egg protein B, the 180 kD protein according to the invention (Table 3) and EST's encoding the peptide sequences were identified in an in-house salmon louse EST database. The full-length cDNA
sequence was successfully assembled based on overlapping ESTs and RACE clones. An in silico analysis of the egg-band B encoding cDNA sequence Vlx (SEQ ID NO: 3), revealed that it is a protein that possesses key features of a Vitelogenin.
Band B in the oocyte is approximately 180 kD, which correlates well with the V6X ORF and with Northern blot transcript analysis (data not shown).
Table 3. The peptide sequences obtained from isolated egg-band B and the identified gene that encodes egg-band B. Indications of protein-domains are also given.
Mw Internal peptide Identified cDNA / aa Signal Protein domain isolated sequences Gene length peptide protein 180 kD 1 GYGGEYSYXVIGS Vlx* 4,747* / Yes LPD-N + VWD
2 EGYLATGQFFEXD 1,521 Table 3.
* See SEQ ID NO: 3 for cDNA sequence One peptide sequence was obtained for egg protein C and one peptide sequence was obtained for egg protein D (Table 4) and EST's encoding the peptide sequences were identified in an in-house salmon louse EST database. A full-length cDNA
sequence was successfully assembled based on overlapping ESTs and RACE clones and revealed that egg protein C and D are encoded by the same gene. According to in silco analysis this gene sequence encodes a protein that possesses key features of a Vitelogenin. The molecular weight of the egg proteins and C and D together is approximately 185 Kda, which correlates well with the open reading frame of the gene and with Northern blot transcript analysis. However, in the L. salmonis oocyte the protein encoded by this gene is apparently processed into one N-terminal part (band D) and one C-terminal part (band C).
Mw Internal peptide Identified cDNA / aa Signal Protein domain isolated sequences Gene length peptide protein 100 kD QGGSTLXSXMPY C%* 5,948* / Yes LPD-N + VWD
85 kD LLSGIPGLRPHFSGIG 1,903 Table 4.
* See SEQ ID NO: 5 for cDNA sequence One peptide sequences was obtained for egg protein E (Table 5) and EST
encoding the peptide sequence was identified in an in-house salmon louse EST database.
The full-length cDNA sequence was successfully assembled based on overlapping ESTs and RACE clones. According to in silco analysis the eggband E cDNA sequence (SEQ ID NO: 7) encodes a protein of unknown function with molecular weight of KDa. This correlates well with Northern blot transcript analysis (data not shown), indicating that egg-band E (79 kDa) has been processed. The ORF encoded protein has a signal peptide and 3 fasciclin (FAS 1) domains, an extracellular domain suggested to represent an ancient cell adhesion domain common to plants and animals.
Table 5. The peptide sequences obtained from isolated egg-band E and the identified gene that encodes egg-band E. Indications of protein-domains are also given.
Mw Internal peptide Identified cDNA / aa Signal Protein domain isolated sequences Gene length peptide protein 79 kD GTWFTPGLISGQSVK Band E* 2,511* / Yes FAS1 x3 Table 5.
* See SEQ ID NO: 7 for cDNA sequence 3. Evaluation of protein antigenicity Each of the purified egg protein A, B, C, D and E (Fig 4-7) used for the immunization of rabbits induced high levels of specific antibodies, as can be seen from figure 8-11.
These antibodies bind only and specifically to either the 200 kD protein, the 180 kD
protein, the 100 kD protein, the 85 kD protein or the 79 kD protein on a Western blot of gels comprising all proteins as antigen (Fig 12-15).
The vaccine antigens (all egg proteins A-E) induced, when used together for the immunization of Atlantic salmon, production of antibodies against the purified kD protein, the 180 kD protein, the 100 kD protein, the 85 kD protein or the 79 kD
protein egg-band, as can be clearly seen from figure 16-19.
Conclusion: it follows from the experiments above that each of the proteins according to the invention; the 200 kD protein, the 180 kD protein, the 100 kD protein, the 85 kD protein or the 79 kD protein of the egg protein preparation are capable of inducing protection against sea lice, are highly immunogenic and are recognized by both antibodies raised against them in rabbits and antibodies raised in fish 5 4. Identification of homolog antigens in other copepod ectoparasites SDS-PAGE and Coomassie total protein staining of egg-proteins from L.
salmonis, Caligus curtus and Caligus rogercresseyi showed that all three species have a similar egg protein pattern (Fig 20a-23a). Western blotting of the same egg proteins demonstrated that each of the rabbit anti L. salmonis egg-bands A, B, C, D and E, 10 corresponding to the 200 kD, 180 kD, 100 kD, 85 kD and 79 kD proteins specifically bind to a homolog protein in both Caligus species (Fig 20b, 21b, 22b, 22c, 23b).
Conclusion: it can be concluded that protection on the basis of the 200 kD, 180 kD, 100 kD, 85 kD and 79 kD protein according to the invention is not only feasible against L. salmonis, but equally well against Caligus spp.
Legend to the figures Figure 1. Prevalence (A) and abundance (B) of adult salmon lice on vaccinated Atlantic salmon smolt 11 weeks post challenge (26 weeks post vaccination).
Figure 2. Frequency and level of salmon lice induced external pathology on vaccinated (tank 2) and control vaccinated (tank 1) Atlantic salmon, 11 weeks post challenge with salmon louse.
Figure 3. SDS-PAGE and Coomassie brilliant blue (total protein stain) analysis of vaccine antigen preparation.
Figure 4. SDS-PAGE and Coomassie brilliant blue (total protein stain) analysis of purified egg-band A (lane 2) and crude vaccine antigen preparation (lane 3).
Molecular weight standard is to the left (lane 1).
Figure 5. SDS-PAGE and Coomassie brilliant blue (total protein stain) analysis of purified egg-band B (lane 2) and crude vaccine antigen preparation (lane 3).
Molecular weight standard is to the left (lane 1).
Figure 6. SDS-PAGE and Coomassie brilliant blue (total protein stain) analysis of purified egg band C (lane 2), D (lane 5) and crude vaccine antigen preparation (duplicated in lanes 3 and 6). Molecular weight standards are in lanes 1 and 4.
Figure 7. SDS-PAGE and Coomassie brilliant blue (total protein stain) analysis of purified egg-band E (lane 1) and crude vaccine antigen preparation (lane 3).
Molecular weight standard is in lane 2.
Figure 8. Level of antibodies against egg-band A protein, in antisera from rabbits immunised with egg-band A or egg-band E (control serum), analysed by ELISA.
ELISA plates were coated with purified egg-band A protein.
Figure 9. Level of antibodies against egg-band B protein, in antisera from rabbits immunised with eggband B or egg-band E (controlserum), analysed by ELISA.
ELISA plates were coated with purified egg-band B protein.
Figure 10. Level of antibodies aginst egg proteins C and D (figure A and B, respectively), in antisera from rabbits immunised with egg band C, D or egg band E
(controlserum). Sera were analysed by ELISA with plates coated with purified eggband C or D (figure A and B, respectively).
Figure 11. Level of antibodies against egg-band E protein, in antisera from rabbits immunised with egg-band E or egg-band D (control serum), analysed by ELISA.
ELISA plates were coated with purified egg-band E protein.
Figure 12. Antigen-specificity of rabbit anti egg-band A antiserum (A2) analyzed by Western blotting using all vaccine proteins as antigen. A3 was incubated with pre-serum. The vaccine antigen used in the Western blotting (egg-band A-E) is shown in lane B2, a total protein stain of the SDS-PAGE. Identical molecular weight standards are shown in lane Al and Bl.
Figure 13. Antigen-specificity of rabbit anti egg-band B antiserum (A2) analyzed by Western blotting using all vaccine proteins as antigen. A3 was incubated with pre-serum. The vaccine antigen used in the Western blotting (egg-band A-E) is shown in lane B2, a total protein stain of the SDS-PAGE. Identical molecular weight standards are shown in lane Al and Bl.
Figure 14. Antigen-specificity of rabbit anti egg band C and anti egg band D
antiserum (A2 and A3 respectively) analyzed by Western blotting using all vaccine proteins as antigen. A4 was incubated with pre-serum. The vaccine antigen used in the Western blotting (egg band A-E) is shown in lane B2, a total protein stain of the SDS-PAGE. Identical molecular weight standards are shown in lane Al and Bl.
Figure 15. Antigen-specificity of rabbit anti egg-band E antiserum (A2) analyzed by Western blotting using all vaccine proteins as antigen. A3 was incubated with pre-serum. The vaccine antigen used in the Western blotting (egg-band A-E) is shown in lane B2, a total protein stain of the SDS-PAGE. Identical molecular weight standards are shown in lane Al and Bl.
Figure 16. Level of antibodies against egg-band A protein, in antisera from 5 Atlantic salmon immunised with the vaccine antigens. ELISA plates were coated with purified egg-band A protein. Control sera are from un-immunised salmon.
Figure 17. Level of antibodies against egg-band B protein, in antisera from 5 Atlantic salmon immunised with the vaccine antigens. ELISA plates were coated with purified egg-band B protein. Control sera are from un-immunised salmon.
Figure 18. Level of antibodies against egg band C protein (a) and egg band D
protein (b), in antisera from 5 Atlantic salmon immunised with the vaccine antigens.
ELISA
plates were coated with purified egg band C protein (a) and purified egg band D
protein (b). Control sera are from un-immunised salmon.
Figure 19. Level of antibodies against egg-band E protein, in antisera from 5 Atlantic salmon immunised with the vaccine antigens. ELISA plates were coated with purified egg-band E protein. Control sera are from un-immunised salmon.
Figure 20. Analysis of egg protein A in Caligus curtus (C. c) and Caligus rogercresseyi (C. r) compared to Lepeophtheirus salmonis (L. s).
(a) SDS-PAGE and Coomassie staining was performed for total protein analysis of all egg proteins. (b) Western blotting was performed using rabbit anti L. s egg protein A
to analyze for cross binding to homologue gene products in Caligus. (c) Rabbit pre-serum was used as negative Western blotting control. Lanes labeled Std contain identical molecular weight standards.
Figure 21. Analysis of egg proteins (A-E) in Caligus curtus (C. c) and Caligus rogercresseyi (C. r) compared to Lepeophtheirus salmonis (L. s).
(a) SDS-PAGE and Coomassie staining was performed for total protein analysis of all egg proteins. (b) Western blotting was performed using rabbit anti L. s egg protein B
to analyze for cross binding to homologue gene products in Caligus. (c) Rabbit pre-. a J
serum was used as negative Western blotting control. Lanes labeled Std contain identical molecular weight standards.
Figure 22. Analysis of egg proteins C and D in Caligus curtus (C. c) and Caligus rogercresseyi (C. r), compared to Lepeophtheirus salmonis (L. s).
(a) SDS-PAGE and Coomassie staining was performed for total protein analysis of all egg proteins. Western blotting was performed using rabbit anti L. s egg protein C (b) and D (c) to analyze for cross binding to homologue gene products in Caligus.
(d) Rabbit pre-serum was used as negative Western blotting control. Lanes labeled Std contain identical molecular weight standards.
Figure 23. Analysis of egg protein E in Caligus curtus (C. c) and Caligus rogercresseyi (C. r) compared to Lepeophtheirus salmonis (L. s).
(a) SDS-PAGE and Coomassie staining was performed for total protein analysis of all egg proteins. (b) Western blotting was performed using rabbit anti L. s egg protein E
to analyze for cross binding to homologue gene products in Caligus. (c) Rabbit pre-serum was used as negative Western blotting control. Lanes labeled Std contain identical molecular weight standards.
SEQUENCE LISTING IN ELECTRONIC FORM
In accordance with Section 111(1) of the Patent Rules, this description contains a sequence listing in electronic form in ASCII text format (file:
30339-128 Seq 20-MAR-08 vl.txt).
A copy of the sequence listing in electronic form is available from the Canadian Intellectual Property Office.
DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.
NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.
NOTE: For additional volumes please contact the Canadian Patent Office.
Claims (48)
1) A 200 kD protein or an immunogenic fragment of said protein, said protein or immunogenic fragment thereof having an amino acid sequence that is at least 70%
identical to the amino acid sequence as depicted in SEQ ID NO: 2.
identical to the amino acid sequence as depicted in SEQ ID NO: 2.
2) A 200 kD protein or an immunogenic fragment of said protein, according to claim 1, characterized in that said protein or immunogenic fragment thereof has a sequence identity of at least 80%, preferably 90%, more preferably 95%, most preferably 100%
identity with the to the amino acid sequence as depicted in SEQ ID NO: 2.
identity with the to the amino acid sequence as depicted in SEQ ID NO: 2.
3) A 200 kD protein or an immunogenic fragment of said protein according to claim 1 or 2, characterized in that said protein or immunogenic fragment thereof is encoded by a nucleic acid sequence as depicted in SEQ ID NO: 1.
4) A 180 kD protein or an immunogenic fragment of said protein, said protein or immunogenic fragment thereof having an amino acid sequence that is at least 70%
identical to the amino acid sequence as depicted in SEQ ID NO: 4.
identical to the amino acid sequence as depicted in SEQ ID NO: 4.
5) A 180 kD protein or an immunogenic fragment of said protein, according to claim 1, characterized in that said protein or immunogenic fragment thereof has a sequence identity of at least 80%, preferably 90%, more preferably 95%, most preferably 100%
identity with the to the amino acid sequence as depicted in SEQ ID NO: 4.
identity with the to the amino acid sequence as depicted in SEQ ID NO: 4.
6) A 180 kD protein or an immunogenic fragment of said protein according to claim 1 or 2, characterized in that said protein or immunogenic fragment thereof is encoded by a nucleic acid sequence as depicted in SEQ ID NO: 3.
7) A 100/85 kD protein or an immunogenic fragment of said protein, said protein or immunogenic fragment thereof having an amino acid sequence that is at least 70%
identical to the amino acid sequence as depicted in SEQ ID NO: 6.
identical to the amino acid sequence as depicted in SEQ ID NO: 6.
8) A 100/85 kD protein or an immunogenic fragment of said protein, according to claim 1, characterized in that said protein or immunogenic fragment thereof has a sequence identity of at least 80%, preferably 90%, more preferably 95%, most preferably 100% identity with the to the amino acid sequence as depicted in SEQ ID
NO: 6.
NO: 6.
9) A 100/85 kD protein or an immunogenic fragment of said protein according to claim 1 or 2, characterized in that said protein or immunogenic fragment thereof is encoded by a nucleic acid sequence as depicted in SEQ ID NO: 5.
10) A 79 kD protein or an immunogenic fragment of said protein, said protein or immunogenic fragment thereof having an amino acid sequence that is at least 70%
identical to the amino acid sequence as depicted in SEQ ID NO: 8.
identical to the amino acid sequence as depicted in SEQ ID NO: 8.
11) A 79 kD protein or an immunogenic fragment of said protein, according to claim 1, characterized in that said protein or immunogenic fragment thereof has a sequence identity of at least 80%, preferably 90%, more preferably 95%, most preferably 100%
identity with the to the amino acid sequence as depicted in SEQ ID NO: 8.
identity with the to the amino acid sequence as depicted in SEQ ID NO: 8.
12) A 79 kD protein or an immunogenic fragment of said protein according to claim 1 or 2, characterized in that said protein or immunogenic fragment thereof is encoded by a nucleic acid sequence as depicted in SEQ ID NO: 7.
13) Vaccine for combating sea lice infection, characterized in that it comprises a 200 kD protein according to claims 1-3 or an immunogenic fragment thereof, and a pharmaceutically acceptable carrier.
14) Vaccine for combating sea lice infection, characterized in that it comprises a 180 kD protein according to claims 4-6 or an immunogenic fragment thereof, and a pharmaceutically acceptable carrier.
15) Vaccine for combating sea lice infection, characterized in that it comprises a 100/85 kD protein according to claims 7-9 or an immunogenic fragment thereof, and a pharmaceutically acceptable carrier.
16) Vaccine for combating sea lice infection, characterized in that it comprises a 79 kD protein according to claims 10-12 or an immunogenic fragment thereof, and a pharmaceutically acceptable carrier.
17) Vaccine for combating sea lice infection, characterized in that it comprises antibodies against a 200 kD protein according to claims 1-3 or against an immunogenic fragment of said protein, and a pharmaceutically acceptable carrier.
18) Vaccine for combating sea lice infection, characterized in that it comprises antibodies against a 180 kD protein according to claims 4-6 or against an immunogenic fragment of said protein, and a pharmaceutically acceptable carrier.
19) Vaccine for combating sea lice infection, characterized in that it comprises antibodies against a 100/85 kD protein according to claims 7-9 or against an immunogenic fragment of said protein, and a pharmaceutically acceptable carrier.
20) Vaccine for combating sea lice infection, characterized in that it comprises antibodies against a 79 kD protein according to claims 10-12 or against an immunogenic fragment of said protein, and a pharmaceutically acceptable carrier.
21) Vaccine according to claim 13-20, characterized in that it comprises an adjuvant.
22) Nucleic acid sequence encoding a 200 kD protein or an immunogenic fragment of said protein, said nucleic acid sequence having at least 70 % identity with the nucleic acid sequence as depicted in SEQ ID NO: 1.
23) Nucleic acid sequence according to claim 22, characterized in that said nucleic acid sequence has at least 80 %, preferably 90 %, more preferably 95 %, most preferably 100% identity with the nucleic acid sequence as depicted in SEQ ID
NO: 1.
NO: 1.
24) Nucleic acid sequence encoding a 180 kD protein or an immunogenic fragment of said protein, said nucleic acid sequence having at least 70 % identity with the nucleic acid sequence as depicted in SEQ ID NO: 3.
25) Nucleic acid sequence according to claim 24, characterized in that said nucleic acid sequence has at least 80 %, preferably 90 %, more preferably 95 %, most preferably 100% identity with the nucleic acid sequence as depicted in SEQ ID
NO: 3.
NO: 3.
26) Nucleic acid sequence encoding a 100/85 kD protein or an immunogenic fragment of said protein, said nucleic acid sequence having at least 70 % identity with the nucleic acid sequence as depicted in SEQ ID NO: 5.
27) Nucleic acid sequence according to claim 26, characterized in that said nucleic acid sequence has at least 80 %, preferably 90 %, more preferably 95 %, most preferably 100% identity with the nucleic acid sequence as depicted in SEQ ID
NO: 5.
NO: 5.
28) Nucleic acid sequence encoding a 79 kD protein or an immunogenic fragment of said protein, said nucleic acid sequence having at least 70 % identity with the nucleic acid sequence as depicted in SEQ ID NO: 7.
29) Nucleic acid sequence according to claim 28, characterized in that said nucleic acid sequence has at least 80 %, preferably 90 %, more preferably 95 %, most preferably 100% identity with the nucleic acid sequence as depicted in SEQ ID
NO: 7.
NO: 7.
30) DNA fragment comprising a nucleic acid sequence as described in claim 22-29.
31) Recombinant DNA molecule comprising a nucleic acid sequence as described in claim 22-29 or a DNA fragment according to claim 30, under the control of a functionally linked promoter.
32) Live recombinant carrier comprising a nucleic acid sequence as described in claim 22-29, a DNA fragment according to claim 30 or a recombinant DNA molecule according to claim 31.
33) Host cell comprising a nucleic acid sequence as described in claim 22-29, a DNA
fragment according to claim 30, a recombinant DNA molecule according to claim or a live recombinant carrier according to claim 32.
fragment according to claim 30, a recombinant DNA molecule according to claim or a live recombinant carrier according to claim 32.
34) Vaccine for combating sea lice infection, characterized in that it comprises a nucleic acid sequence described in claim 22-29, a DNA fragment according to claim 30, a recombinant DNA molecule according to claim 31, a live recombinant carrier according to claim 32, or a host cell according to claim 33, and a pharmaceutically acceptable carrier.
35) Vaccine according to claims 13-21 or 34, characterized in that it comprises an additional antigen derived from a virus, organism or micro-organism pathogenic to fish, an antibody against said antigen or genetic information encoding said antigen.
36) Vaccine according to claim 35, characterized in that said virus, organism or micro-organism pathogenic to fish is selected from the group of infectious pancreatic necrosis virus (IPNV), striped jack nervous necrosis virus (SJNNV), infectious salmon anaemia virus sea lice), infectious haematopoietic necrosis virus (IHNV), viral haemorrhagic septicaemia virus (VHSV), Pancreas Disease virus (SPDV), infectious salmon anaemia virus, Flexibacter columnaris, Edwardsialla ictaluri, E. tarda, Yersinia ruckeri, Pasteurella piscicida, Vibrio anguillarum, Aeromonas salmonicida and Renibacterium salmoninarum.
37) Vaccine according to claims 34-36, characterized in that it comprises an adjuvant.
38) A 200 kD protein or an immunogenic fragment thereof, according to claims 1-3 for use in a vaccine.
39) A 180 kD protein or an immunogenic fragment thereof, according to claims 4-6 for use in a vaccine.
40) A 100/85 kD protein or an immunogenic fragment thereof, according to claims 7-9 for use in a vaccine.
41) A 79 kD protein or an immunogenic fragment thereof, according to claims 10-12 for use in a vaccine.
42) A nucleic acid sequence according to claim 22-29, a DNA fragment as described in claim 30, a recombinant DNA molecule as described in claim 31, a Live Recombinant Carrier as described in claim 32 or a host cell as described in claim 33 for use in a vaccine
43) Use of a 200 kD protein or an immunogenic fragment thereof, according to claims 1-3 for the manufacturing of a vaccine for combating sea louse infections.
44) Use of a 180 kD protein or an immunogenic fragment thereof, according to claims 4-6 for the manufacturing of a vaccine for combating sea louse infections.
45) Use of a 100/85 kD protein or an immunogenic fragment thereof, according to claims 7-9 for the manufacturing of a vaccine for combating sea louse infections.
46) Use of a 79 kD protein or an immunogenic fragment thereof, according to claims 10-12 for the manufacturing of a vaccine for combating sea louse infections.
47) Use of a nucleic acid sequence as described in claim 22-29, a DNA fragment as described in claim 30, a recombinant DNA molecule as described in claim 31, a Live recombinant Carrier as described in claim 32 or a host cell as described in claim 33 for the manufacturing of a vaccine for combating sea louse infections.
48) Method for the preparation of a vaccine according to claims 13-21 or 34-36, said method comprising the admixing of a 200 kD protein according to claims 1-3 or antibodies against said 200 kD protein, a 180 kD protein according to claims 4-6 or antibodies against said 180 kD protein, a 100/85 kD protein according to claims 7-9 or antibodies against said 100/85 kD protein, a 79 kD protein according to claims or antibodies against said 79 kD protein, a nucleic acid sequence according to claim 22-29, a DNA fragment according to claim 30, a recombinant DNA molecule according to claim 31, a live recombinant carrier according to claim 32 or a host cell according to claim 33, and a pharmaceutically acceptable carrier.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05109259 | 2005-10-05 | ||
EP05109258.3 | 2005-10-05 | ||
EP05109260 | 2005-10-05 | ||
EP05109260.9 | 2005-10-05 | ||
EP05109259.1 | 2005-10-05 | ||
EP05109261 | 2005-10-05 | ||
EP05109258 | 2005-10-05 | ||
EP05109261.7 | 2005-10-05 | ||
PCT/EP2006/066978 WO2007039599A1 (en) | 2005-10-05 | 2006-10-03 | Novel sea lice vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2624486A1 true CA2624486A1 (en) | 2007-04-12 |
Family
ID=37696028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002624486A Abandoned CA2624486A1 (en) | 2005-10-05 | 2006-10-03 | Novel sea lice vaccine |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1934247A1 (en) |
JP (1) | JP2009511005A (en) |
CA (1) | CA2624486A1 (en) |
DK (2) | DK200800635A (en) |
NO (1) | NO20081541L (en) |
TW (1) | TW200801034A (en) |
WO (1) | WO2007039599A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006010265A1 (en) * | 2004-07-28 | 2006-02-02 | National Research Council Of Canada | Recombinant vaccines against caligid copepods (sea lice) and antigen sequences thereof |
CU23634A1 (en) * | 2007-05-31 | 2011-02-24 | Ct Ingenieria Genetica Biotech | SEQUENCES OF NUCLEIC ACID AND AMINO ACIDS, AND VACCINE FOR THE CONTROL OF INFESTATIONS BY ECTOPARASITES IN FISH |
CA2705544A1 (en) | 2007-11-19 | 2009-05-28 | Calanus As | Bioactive copepod-compositions, processes for the production thereof, and use thereof to prevent or treat hosts infested by phylogenetically similar ectoparasites |
GB201902425D0 (en) * | 2019-02-22 | 2019-04-10 | Benchmark Animal Health Ltd | Sea lice antigens and vaccines |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006010265A1 (en) * | 2004-07-28 | 2006-02-02 | National Research Council Of Canada | Recombinant vaccines against caligid copepods (sea lice) and antigen sequences thereof |
-
2006
- 2006-09-27 TW TW095135847A patent/TW200801034A/en unknown
- 2006-10-03 WO PCT/EP2006/066978 patent/WO2007039599A1/en active Application Filing
- 2006-10-03 EP EP06806932A patent/EP1934247A1/en not_active Withdrawn
- 2006-10-03 CA CA002624486A patent/CA2624486A1/en not_active Abandoned
- 2006-10-03 JP JP2008533995A patent/JP2009511005A/en active Pending
-
2008
- 2008-03-31 NO NO20081541A patent/NO20081541L/en not_active Application Discontinuation
- 2008-05-05 DK DK200800635A patent/DK200800635A/en not_active Application Discontinuation
-
2010
- 2010-03-05 DK DKPA201070087A patent/DK201070087A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TW200801034A (en) | 2008-01-01 |
DK201070087A (en) | 2010-03-05 |
WO2007039599A1 (en) | 2007-04-12 |
EP1934247A1 (en) | 2008-06-25 |
DK200800635A (en) | 2008-05-05 |
JP2009511005A (en) | 2009-03-19 |
NO20081541L (en) | 2008-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2622610C (en) | Fish vaccine | |
JP3780256B2 (en) | Antigenic protein of white spot syndrome virus and use thereof | |
US20100150958A1 (en) | Methods and Compositions for Use of a Coccidiosis Vaccine | |
JP2009077713A (en) | NUCLEIC ACIDS ENCODING RECOMBINANT 56 AND 82 kDa ANTIGENS FROM GAMETOCYTES OF EIMERIA MAXIMA AND THEIR USE | |
CA2624486A1 (en) | Novel sea lice vaccine | |
Mao et al. | Expression of Vibrio harveyi ompK in the yeast Pichia pastoris: The first step in developing an oral vaccine against vibriosis? | |
CA2950239C (en) | A fish vaccine comprising a fusion protein having a fish translocaion sequence | |
EP1334197B1 (en) | Yeast derived vaccine against ipnv | |
US7279167B2 (en) | Infectious Salmon Anaemia virus vaccine | |
JP7467027B2 (en) | Yeast vaccine vectors containing immunostimulatory and antigenic polypeptides and methods of using same | |
WO2003000900A1 (en) | White spot syndrome virus vaccine | |
CA2442346C (en) | Nucleic acids encoding isav polypeptides | |
CA2498249C (en) | Ostertagia vaccine | |
Xicheng et al. | Embryo vaccination against eimeria tenella and e. acervulina infections using recombinant proteins and cytokine adjuvants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |
Effective date: 20130507 |